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Abstract 
Aims: The overall aim of this thesis was to increase our knowledge about the 
epidemiology, diagnostics and treatment of upper tract urothelial carcinoma (UTUC).  
For paper 1, the aim was to obtain contemporary knowledge about UTUC incidence, 
UTUC tumour and patient characteristics, and possible changes over time using 
national, population based data. For paper 2 and 3, the aim was to evaluate current 
standard diagnostics before radical nephroureterectomy (RNU), and see if our findings 
could be used for selecting patients for intensified treatment. Further, we aimed to 
evaluate a previously published diagnostic model through an external validation. For 
paper 4, we aimed to evaluate the outcomes of endoscopic treatment for UTUC given 
at our hospital with particular emphasis on tumour grade.  
Materials and methods: For paper 1, the study population included all patients 
registered with an International Classification of Diseases tenth version (ICD-10) 
diagnosis code C65 (cancer of the renal pelvis) and C66 (cancer of the ureter) at the 
Norwegian Cancer Registry (NCR) during 1999-2018. After an inclusion/exclusion 
process, 3096 cases of verified UTUC in 2818 patients were included in the study. 
For purpose of comparisons with other urothelial cancers and renal cell carcinoma 
(RCC), 24467 cases of bladder cancer (BC), 287 cases of urethral cancer, and 13619 
cases of RCC were drawn from the same main database during the same time period. 
Statistical analyses were performed to calculate UTUC age standardized rates (ASR), 
UTUC incidence rates compared to other urothelial cancers and RCC, and to look for 
possible changes over time regarding incidence rates, epidemiological variables and 
survival.  
For paper 2 and 3, all patients treated with a RNU for UTUC at Haukeland University 
Hospital and Vestfold Hospital Trust during 2005-2017 were evaluated. After an 
inclusion/exclusion process, 179 patients were included in the study. For paper 2, all 
available preoperative features regarding the patients, the CT scan and the 
ureteroscopy (URS) were analysed regarding their abilities to predict tumour stage 
and survival. Further analyses were performed to evaluate if our findings could be 
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used to select patients for intensified treatment. For paper 3, 162 of the 179 patients 
had complete dataset needed for external validation of the published Margulis 
nomogram and were included in the study. An external validation assessing both 
model calibration and discrimination was performed.  
For paper 4, 43 patients treated endoscopically with curative intent at Haukeland 
University Hospital 2001-2012 were included. Statistical analyses were performed 
regarding survival, kidney protections rates and recurrence both for the whole cohort 
and stratified by indication for treatment and tumour grade.  
Results: Paper 1. The ASR according to the European standard population was 3.88 
for the whole period, increasing significantly from 3.21 to 4.70 from the first to last 
five-year period, corresponding to an estimated annual increase of 2.5%. The 
proportion of UTUC compared to all urothelial cancers and RCC significantly 
increased. UTUC constituted 12.6% of all urothelial cancers in Norway during 2014-
2018. Mean age at diagnosis increased from 71.8 to 73.9 years during the study 
period. The 5-year overall survival (OS) increased moderately over time from 44.3% 
to 51.7% comparing last decade with the first. In paper 2, we found that local 
invasion and the presence of pathological lymph nodes at CT predicted both tumour 
stage at final pathology and survival in uni-and multivariate regression analyses. 
These variables can be used when selecting patients for intensified treatment. 
Diagnostic URS has a limited role in preoperative tumour staging. In paper 3, we 
found an overall high concordance between predicted risk of non-organ confined 
disease using the Margulis nomogram, and the observed risk in our cohort. The 
accuracies of both the predicted and observed risks were 0.83 to indicate adequate 
model discrimination. The calibration was assessed in a scatter plot where the overall 
concordance was high, quantified with a Cronbach Alpha of 0.96. There seems to be 
a mis-calibration at the low-risk levels. In paper 4 we found that the five –year 
disease specific survival (DSS) of patients treated endoscopically with an elective 
indication or for a low grade tumour (according to the World Health organization 
(WHO) classification from 2004) was high (DSS 94% and 96% respectively). The 
survival of patients treated with an imperative indication or for a high-grade tumour 
were significantly lower (DSS 41% and 39% respectively). 25 of 43 patients were 
assessed as tumour free at one point during follow-up, and the five-year recurrence 
free survival among these patients were 76%. The five-year kidney protection rate 
(KPR) for patients with low-grade tumours was 60%. The KPR for patients tumour 
free at first follow-up (14 of 43), was 90%.  
Conclusions: The incidence of UTUC in Norway was higher than expected, and 
increasing. Patient age at diagnosis is increasing. Local invasion and pathological 
lymph nodes at CT can predict tumour stage and survival after RNU, and can be used 
when selecting patients for intensified treatment. The Margulis nomogram is 
considered validated for clinical use. Tumour grade according to the WHO 
classification from 2004 is a strong predictor of outcomes after endoscopic treatment 
for UTUC, and should be considered when selecting patients for this treatment 
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1. Introduction 
1.1.1 Normal anatomy and function of the upper urinary tract 
The upper urinary tract (UUT) consists of the kidneys, the renal pelvis and the 
ureters. While the urine is produced in the kidney, the collecting system (the calyces, 
the renal pelvis and the ureters) transports the urine from the calyces to the urinary 
bladder. Anatomically, the urothelial lining of the upper urinary tract is similar to the 
urothelial lining of the bladder, but the thickness of the muscle layers are markedly 
thicker in the bladder. The specialized epithelium of the urinary organs previously 
designated transitional epithelium, is currently referred to as the urothelium. The 
urothelium consists of three layers, see Figure 1. The innermost basal cells consist of 
small, long-living cells which are precursors for the outer layers. The intermediate 
layer consists of pyriform cells with a differing number of cell layers. The outer cells 
are large, rounded or cuboidal. These specialized cells are referred to as umbrella 
cells [1]. This configuration is well adapted for increasing or decreasing the surface 
area to accommodate different volumes of urine. The urothelium is a barrier for 
water, ions, solutes and pathogens. It also serves a sensory organ transmitting signals 
of its milieu to the underlying nervous systems [2]. The urothelial lining is continuous 
from the calyces to the ureteral ostium. The innermost layer is the urothelium, deeper 
lies the sub epithelial connective tissue (the lamina propria), the muscularis propria 
and the peripelvic/periureteric fatty tissue. In the calyces, the renal pelvis and upper 
ureter, the muscularis propria consists of two layers of smooth muscle. In the lower 
part of the ureter, an additional third layer of smooth muscle is present. All three 
layers merge with the corresponding muscle layers of the bladder as the ureters enter 
the bladder wall [3]. 
1.1.2 Anatomical considerations 
The thin muscularis propria of the UUT has implications for the proper staging of 
tumours in the UUT, as it can be hard to distinguish superficial tumours from 





Figure 1. Illustration of a normal urothelium with umbrella cells in the outermost 
layer.  
1.1.3 Pathology of urothelial carcinoma of the upper urinary tract  
UTUC can be defined as a urothelial carcinoma arising from the urothelium in the 
calyces, the kidney pelvis, or the ureters down to and including the ureteral ostium of 
the bladder. Pure UTUC and UTUC with variant histology constitute more than 90% 
of all carcinomas arising from the lining of the UUT, but pure squamous cell 
carcinoma, adenocarcinoma, sarcomas, lymphomas and other tumours can also arise 
from the UUT [4]. Further description of non-urothelial carcinomas in the UUT is 
beyond the scope of this thesis.  
1.2 Epidemiology 
1.2.1 Incidence 
Compared to bladder cancer, UTUC is relatively uncommon. The incidence is 
typically referred to be 1-2:100.000, or 5-10% of all urothelial carcinomas. The 
yearly publication from the American Cancer Society is often quoted as a reference 
for these incidence figures [5].  
1.2.2 Calculation of age standardized rates 
The incidence of a disease in a population is typically referred to as an incidence rate 
per 100.000 people of that population. The crude rate of a disease is the number of 
new cases per year / (total population/100.000). While some cancers are common 
among children or adolescents, most cancers have an increasing incidence with 
increasing age [6]. The incidence of a disease will then depend on the age distribution 
in the population the incidence rates are gathered from. Since the age distribution in 
different parts of the world is highly variable, it is standard to present incidence rates 
as ASRs to make results from incidence studies from different regions or time periods 
more comparable. The most common way to perform standardization is by direct age-
standardization [7]. The crude rates are by that method adjusted to a chosen standard 
population. Many such standard populations are available with quite different age 
composition, as can be seen in Table 1.  
 
 
Age World std. 
1966  
European 
std. 1976  
American 




std.    2013 
00-04 0,120 0,08 0,069135 0,059 0,05 
05-09 0,100 0,07 0,072533 0,066 0,055 
10-14 0,090 0,07 0,073032 0,062 0,055 
15-19 0,090 0,07 0,072169 0,058 0,055 
20-24 0,080 0,07 0,066478 0,061 0,06 
25-29 0,080 0,07 0,064529 0,068 0,06 
30-34 0,060 0,07 0,071044 0,073 0,065 
35-39 0,060 0,07 0,080762 0,073 0,07 
40-44 0,060 0,07 0,081851 0,07 0,07 
45-49 0,060 0,07 0,072118 0,069 0,07 
50-54 0,050 0,07 0,062716 0,074 0,07 
55-59 0,040 0,06 0,048454 0,061 0,065 
60-64 0,040 0,05 0,038793 0,048 0,06 
65-69 0,030 0,04 0,034264 0,041 0,055 
70-74 0,020 0,03 0,031773 0,039 0,05 
75-79 0,010 0,02 0,026999 0,035 0,04 
80-84 0,005 0,01 0,017842 0,024 0,025 
85+ 0,005 0,01 0,015508 0,019 0,025 
Sum 1 1 1 1 1 
% >70 years 4% 7% 9.3% 11.7% 14% 
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Table 1. The table shows some different standard populations that can be used for 
calculation of age standardized incidence rates. Note the different weights, especially 
at high ages.   
In the World standard population from 1966, people aged over 70 years constitute 
only 4% of the total population. In comparison people over 70 years constitute 14% 
of the latest updated European standard population. This is important to bear in mind 
when discussing UTUC incidence, since it is a disease which predominantly drab the 
elderly. For example, adjusting UTUC crude rates to the 2013 version of the 
European standard population will result in markedly different (higher) ASRs than if 
the crude rate was adjusted to the World standard of 1966.  
1.2.3 Published incidence rates 
The published series on UTUC incidence have shown conflicting results. Three 
historic cohorts from the USA, the Netherlands and England have demonstrated an 
increasing incidence. In England, the age standardized incidence rate for men 
increased from 1.2 to 1.6 during 1985-2009, while the incidence for women increased 
from 0.5 to 0.8 [8]. An American study found a more moderate increase from 1.88 to 
2.06 from 1973 to 2005 [9]. A Dutch study described an increase from 2.10 to 2.40 
from 1995-2005 [10]. An Australian study found a stable and relatively low incidence 
of 1.4 from 2001-2011[11], while a Danish study using a more historic cohort 
described an increase in incidence until 1985, followed by a decline to 2.45 for men 
and 1.25 for women 1985-2003 [12]. 
Two recent publications have also shown conflicting results. In a population based 
Dutch study, an increasing ASR (adjusted to the European standard 1976) from 2.0 -
3.2 was reported during 1993-2017 [13]. Contrary to this, a study based on the 
American SEER database found a decreasing incidence in the USA from 1.3-1.1 
adjusted to the American standard population [14].  
Especially high incidences of UTUC have been registered in South Eastern Taiwan, 
with a probable relation to Blackfoot disease caused by arsenic in the drinking water, 
a known risk factor for UTUC [15].  At the Balkan a high UTUC incidence has also 
been reported, related to environmental exposure to aristolochic acid. UTUC 
constitute up to 50% of all urothelial carcinomas in these areas [16]. 
1.2.4 Age, sex and anatomical location 
Mean age at diagnosis is increasing, and is in the more recent cohorts reported to be 
in the range 70-74 years [9, 13]. A majority (61%-77%) of the patients are reported to 
be men, and a majority (51%-66%) of the tumours are located in the renal pelvis [9, 
11, 13]. 
1.2.5 Previous or synchronous bladder cancer  
Previous and synchronous BC is described in 14-28% and 10-12% of UTUC patients 
respectively [17, 18]. 
1.3 Risk factors 
1.3.1 Smoking 
Smoking is associated with a 3-7 fold increase in risk of UTUC. The increased risk is 
dose-dependent. Smoking cessation > 10 years reduces UTUC risk [19, 20]. It also 
adversely affects prognosis after RNU [21].  
1.3.2 Aristolochic Acid 
Aristolochic acid is a carcinogenic compound found in the aristolochiaceae plant, 
commonly used in herbal medicine. It is a known risk factor for kidney disease, liver 
disease and UTUC. Exposure to aristolochic acid is shown to be the cause of Balkan 
nephropathy, where unusually high incidences of UTUC have been reported [16]. In 
China, exposure to aristolochic acid is a suggested factor to explain the unusually 
high UTUC incidence among women [22].  
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1.3.3 Alcohol consumption 
Alcohol consumption >15 gram/day compared to non-drinking is shown to be a risk 
factor for UTUC [23]. 
1.3.4 Lynch syndrome 
Hereditary nonpolyposis colorectal cancer (Lynch syndrome) is an autosomal 
dominant syndrome associated with colorectal cancer, UTUC and other cancers. The 
cumulative risk of UTUC for patients with Lynch syndrome is estimated to 3-14% 




At diagnosis UTUC patients can present with local symptoms (haematuria, flank 
pain), systemic symptoms (anorexia, weight loss, fevers etc.) or no symptoms 
(incidental finding at imaging or during endoscopy). In one publication, local 
symptoms were most common (61%), followed by no symptoms (33%) and systemic 
symptoms (6%) [26]. Haematuria was the most common presenting symptom 
described in 73% of UTUC patients in another patient series [27]. Both these studies 
found that the presence of systemic symptoms at diagnosis was associated with a 
worse prognosis.  
1.4.2 Imaging 
Computed Tomography Urography 
Historically, retrograde or conventional intravenous ureteropyelography was the 
imaging method of choice in the diagnosis of UTUC. As computed tomography 
urography (CTU) technology improved and results showed that CTU was superior to 
other modalities, CTU took over as standard imaging modality for tumours in the 
UUT [28, 29]. In a recent meta-analysis, the pooled sensitivity and specificity in 
setting the correct diagnosis for UTUC in the reviewed publications using multi 
detector CTU was 92% and 95% respectively [30].    
Regarding the staging of UTUC, the predictive abilities of CTU is more debatable. 
The presence of hydronephrosis has been found to predict advanced stage UTUC in 
several publications [31, 32]. Other authors have however concluded that 
hydronephrosis is not a risk factor for tumour stage [33, 34]. Despite some conflicting 
results, hydronephrosis at diagnosis is generally accepted as a predictor of advanced 
tumour stage and poor prognosis [25]. Radiological stage is in two smaller studies 
found to predict pathological tumour stage with a sensitivity of 67-75% and a 
specificity of 84-97% [35, 36]. Local invasion at CTU defined as invasion into the 
renal parenchyma, the peripelvic or periureteric tissue, is shown to be a predictor of 
non-organ confined disease (NOCD, pT3+ and/or N+) in two published diagnostic 
models [37, 38]. Tumour size is in one multicentre study found to be a predictor of 
NOCD [39].  
 Magnetic resonance urography 
Available data on magnetic resonance imaging (MRI) in the preoperative evaluation 
of UTUC is limited. The apparent diffusion coefficient (ADC) value measured in a 
diffusion weighted MRI was in one study found to be significantly lower for high-
grade compared to low-grade UTUC [40]. Another study found that a low ADC value 
was associated with increased metastatic potential [41]. The use of diffusion weighted 
images in addition to conventional MRI was described to improve tumour staging in 
another study [42]. It is possible that ADC could be a potential biomarker for 
aggressive disease and prognosis. Due to limited data available, the use of MRI in the 
evaluation and staging of UTUC is only recommended when a CTU is 
contraindicated [25].  
Positron Emission Tomography  
One study has described a sensitivity and specificity of 82% and 84% respectively 
when using 18F-fluorodeoxyglucose positron emission tomography in the detection of 
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lymph node metastasis in patients treated with RNU and lymph node dissection 
(LND) for UTUC [43]. The usefulness of positron emission tomography in the 
diagnosis of UTUC has to be confirmed in other studies before it can be 
recommended for daily practice.  
1.4.3 Ureteroscopy with biopsy and cytology 
URS with biopsy and selective cytology in situ is recommended as a part of 
diagnostic work-up for suspected UTUC if the results of the URS would influence 
treatment strategy [25]. URS is particularly useful if a nephron sparing surgery (NSS) 
is considered. If the UUT is accessible for a URS, it allows visual inspection of 
tumour location, potential multifocality and evaluation of tumour size. Visual 
assessment of tumour grade and tumour traits (papillary, broad based etc.) is possible, 
but not always accurate [44].  
Ureteroscopic biopsy 
Tumour biopsy during URS is possible using multiple available tools, both 
endoscopic forceps and baskets. Back loaded forceps allowing larger biopsy 
specimens have emerged as a biopsy alternative [45]. In a prospective study, biopsies 
taken with standard forceps, back loaded forceps and basket were compared [46]. 
Biopsy with basket was found to be superior to both forceps devices, and the back 
loaded forceps was found superior to conventional forceps. Discordance between 
tumour grade at URS biopsy and final histopathological evaluation after RNU has 
been described in several papers. Upgrading from low-grade tumour at biopsy to high 
grade histology after RNU was in a large meta-analysis concerning >2000 biopsies 
with subsequent RNU reported to be 32% [47]. The use of confocal laser 
endomicroscopy during URS is a novel method for peroperative visual grading of 
UTUC. Initial results are promising, but needs further verification before it can be 
taken into clinical practise [48].  
Cytology 
A urinary cytology sample may be obtained from the bladder (voided or catheterized) 
or as a selective sample taken via ureteral catheterization or in situ during URS. The 
cytology specimen is evaluated microscopically for cytomorphological features and 
classified according to the Paris classification [49]. The sensitivity of cytology to 
detect low-grade tumours is low, and the aim of the cytology sample is generally to 
detect high-grade tumours. Because of the described upgrading from biopsy to final 
pathology, cytology is potentially important especially among patients with low-
grade biopsy considered for endoscopic treatment. Cytology can in some cases reveal 
a true high-grade tumour when the biopsy is described as low-grade.   
However, the sensitivity of conventional cytology in detecting high-grade UTUC is 
described to be relatively low; in the range of 39-56% [50, 51]. In the study from 
Messer et al. the sensitivity increased when analysing the samples taken using 
selective ureteral catheterization only. In a prospective study using a very strict 
protocol for the collection of in situ barbotage cytology during URS, the sensitivity of 
the cytology increased to 91% [52].  
1.4.4 Diagnostic predictive models  
Several predictive diagnostic models have been presented using patient variables or 
variables from imaging, URS, biopsy, cytology, blood samples, or a combination of 
these [37, 38, 53, 54]. The aims of these models have been to use preoperative 
variables to predict muscle invasive disease (MID) or NOCD at final pathology after 
RNU. The idea is that a prediction MID or NOCD preoperatively can be used in 
decision making regarding the potential use of neoadjuvant chemotherapy or 
extended LND during RNU. The use of diagnostic models will be discussed further in 
the discussion part of this thesis.  
1.5 Staging and Classification systems 
1.5.1 UTUC classification and staging 
UTUC is histopathologically classified in the same manner as BC. Distinctions 
between non-invasive, invasive UTUC and carcinoma in situ (CIS) can be made. 
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Approximately 75% of the tumours are pure urothelial carcinomas, but variant 
histology can also occur with several variants described [55]. The presence of variant 
histology is associated with a worse prognosis.  
Table 2. The table describes the TNM classification for UTUC [56]. The 
classification of UTUC is similar to the TNM for bladder cancer, but simpler in some 
aspects.  
T – PRIMARY TUMOUR  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
 
Ta Non-invasive papillary carcinoma 
 
Tis Carcinoma in situ 
T1 Tumour invades subepithelial connective tissue 
T2 Tumour invades muscularis 
T3 (Renal pelvis) Tumour invades beyond muscularis into peripelvic fat or renal 
parenchyma 
(Ureter) Tumour invades beyond muscularis into periureteric fat 
T4 Tumour invades adjacent organs or through the kidney into perinephric fat 
N - REGIONAL LYMPH NODES 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single lymph node 2 cm or less in the greatest dimension 
N2 Metastasis in a single lymph node more than 2 cm, or multiple lymph nodes 
M - DISTANT METASTASIS 
M0 No distant metastasis 
M1 Distant metastasis 
 
1.5.2 Tumour grading    
In 1973 the WHO presented a three-tiered grading system for urothelial carcinomas 
that was the reference until the revised ISUP/WHO grading was adopted and 
published by WHO in 2004 [57, 58]. An updated version was presented in 2016 
without major changes [59]. In the WHO classification from 1973, the grading of 
urothelial carcinomas was poorly defined. Grade 1 was described as tumours having 
minimal anaplasia, and grade 3 having severe degrees of anaplasia, rendering grade 2 
as a large group in between and not otherwise defined. In contrast, the two-tiered 
WHO/ISUP grading system from 2004 utilizes specific histologic and cytological 
criteria for the distinction of low- and high-grade tumours. Briefly, the WHO 1973 
was based on three grades with increasing cytological atypia. In the WHO/ISUP 2004 
grading system, however,  low-grade carcinomas give a predominant impression of 
both architectural and cytological order by scanning magnification, with minimal 
nuclear atypia (Figure 2a), while high-grade carcinomas are characterized by 
architectural disorder, marked nuclear atypia and mitosis frequently found at all 
levels of the urothelium (Figure 2b). Tumours are in general graded according to the 
highest grade found.  
                      
 
 
There was a delay in the implementation of the new grading system, so many 
publications regarding UTUC have used the 1973 grading system when presenting 
their patients. It is necessary to be familiar with both the new and the old grading 
system when reading papers regarding UTUC.  
Fig 2a. Low-grade 
urothelial carcinoma  
Fig 2b. High-grade 
urothelial carcinoma  
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1.6 Prognosis and survival outcomes 
1.6.1 Natural history 
The literature on the natural course of UTUC treated with no-curative intent is sparse. 
Two population based studies using different cohorts of patients treated non-
surgically for UTUC is available [60, 61]. The study populations consisted of 8% and 
11% of their respective cohorts of UTUC patients. Median OS was 1.9 and 2.2 years, 
and 3 year cancer specific survival (CSS) was 74%. Median age was 79 and 81 years, 
significantly higher than the age of patients treated surgically in the cohorts the 
samples were drawn from. One of the studies evaluated potential effects of treatment 
with chemo- or radiotherapy, but found no indication that such treatment improved 
survival outcomes in patients treated non-surgically. 
1.6.2 Outcomes after RNU 
Open RNU is considered the gold standard treatment for UTUC, and outcomes after 
RNU is therefore considered the main reference when discussing UTUC prognosis. 
The unadjusted five-year CCS in large cohorts after RNU are in the range 74-87% 
[62-65]. The primary predictors for outcome are tumour stage and grade at final 
pathology after RNU [25]. Several other variables are also found to predict outcomes. 
The variables that determine prognosis after RNU can be split into preoperative 
patient or tumour related factors and postoperative tumour related factors. 
1.6.3 Preoperative patient related factors 
Age  
Higher age has been shown to be a predictor of lower OS and CSS in several studies 
[66, 67]. However, other studies have shown that age is not an independent predictor 
of CSS when adjusting for all other factors in a multivariate analysis [68].  
Smoking  
Smoking is a known risk factor for development of UTUC. It is also recognized as a 
predictor of poorer survival outcomes. In a multicentre study of 864 patients treated 
with RNU for UTUC, the patients were stratified according to tobacco consumption, 
and survival outcomes were analysed. The smokers had a lower CSS compared to 
never smokers. Previous smokers who quit >10 years showed an improved CSS 
compared to smokers who quit < 10 years ago [69].  Later studies have shown an 
increased risk of disease progression after RNU among smokers [21]. 
Genetic and molecular markers  
Genetic studies have concluded that UTUC has a different mutation profile than BC. 
Mutations in the FGFR3, TP53 and RB1 gene have been identified. While mutations 
in the FGFR3 gene are more frequent in low-grade than high-grade UTUC, mutations 
in TP53 and RB1 were more common in high-grade UTUC and were associated with 
reduced OS [70, 71].  
A reduced level of E-Cadherin (a protein involved in the stability of intercellular 
adhesion in the urothelium) has been shown to be a predictor of aggressive UTUC 
and reduced survival after RNU in univariate analyses [72]. The presence of 
programmed cell death protein 1 has been shown to be a predictor of poor survival 
while the presence of programmed cell death ligand has been reported as a predictor 
of favourable survival outcomes [73, 74]. Several other molecular markers have been 
tested in smaller studies showing different potential as predictors of outcome but 
further research is needed before any of these can be integrated in the daily clinical 
practice.  
Other patient related factors 
Systemic symptoms at diagnosis are shown to be predictors of worse survival 
outcomes [26, 27]. A higher preoperative ASA score is demonstrated to have a 
negative effect on CSS [75]. Similarly, pre-operative anaemia [76], malnutrition [77] 
as well as obesity [78], hypoalbuminemia [79] and a reduced De Ritis ratio [80] 
(aspartate aminotransferase/alanine aminotransferase ratio) have shown to have 
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negative impact on survival outcomes after RNU. Neither gender nor ethnicity is 
regarded to be independent risk factors for survival after RNU.  
1.6.4 Preoperative tumour related factors 
The presence of multifocality has been described as a negative predictor of survival 
outcomes [81, 82]. Despite some contradictory results in the literature, ureteral 
location is in general considered to be a predictor for poorer survival [25, 82, 83]. The 
presence of hydronephrosis has been described to be a predictor for poorer survival 
outcomes [84].     
Presence of previous or synchronous bladder cancer 
A large multi institutional study from Japan, patients with previous or synchronous 
BC demonstrated a poorer OS compared to patients without BC [18].  Another 
smaller study from South Korea found that previous or synchronous BC predicted 
bladder and local recurrence, but not survival [85]. 
Surgical delay 
One population based study suggested that surgical waiting time >120 days could 
have a negative impact on prognosis [86]. Other studies have shown that shorter 
delays in time from diagnosis to final treatment does not impact prognosis allowing 
for supplementary investigations of the patient if indicated [87, 88].  
Hospital volume 
A recent American study reported improved survival both in the short- and long term 
for high-volume centres compared to low-volume centres. The authors conclude that 
these differences can be both due to surgeon volume, but also due to better ancillary 
services available at high-volume centres [89].    
1.6.5 Postoperative tumour related factors  
Tumour stage (pT) 
Multi institutional studies have shown that outcomes after RNU are strongly 
dependent upon pT-stage. The 5-year CSS according to stage has been reported to be 
94% for Ta tumours, 91-94% for T1 tumours, 75-86% for T2 tumours, 54-65% for 
T3 tumours, and 13-55% for T4 tumours [63, 90].  
Nodal status (pN) 
Survival outcomes are also strongly dependent upon pN-status. The 5-year CSS for 
patients with node positive disease is referred to be 34-35% vs 77% for pNx/N0 
patients [63, 90]. OS for node positive patients have been reported in the same range 
[91], indicating that death due to UTUC is predominant over other causes of overall 
mortality among node positive patients.   
Outcome for patients with node positive disease is however also dependent on tumour 
stage. Lugghezzani et al. found that node positive patients with pT1-2 had a 
significantly higher 5-year CSS compared to node positive patients with pT3-4, (69% 
vs 29%, p=0.006) respectively [63].  
Tumour grade 
Histological tumour grade according to the two-tiered WHO/ISUP grading system is 
shown to be an independent strong predictor of survival outcomes after RNU. 
Unadjusted 5-year CSS for high-grade UTUC is referred to be 57% vs 88% for low-
grade tumours [90]. Many published papers on UTUC have presented tumour grade 
data using the older three-tiered grading system. A survival benefit for lower vs 
higher tumour grades is also described using the older three-tiered grading system 
[92].  
Tumour architecture 
A description of tumour architecture is a part of the gross macroscopic evaluation 
performed by the pathologist on the RNU specimen postoperatively. Sessile 
architecture is described as flat growing with an invasive pattern as opposed to 
papillary, which is often polypoid and frequently with a thin tumour stem [93]. 
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Sessile architecture is reported to be present in 20-25% of the patients [90], and is 
reported to be a predictor of poor survival outcomes (five-year CSS 65% for sessile 
tumour architecture vs 90% for papillary tumour architecture, p<0.001 [93]. 
Other postoperative tumour related factors 
In addition to the described factors, the presence of lymphovascular invasion [94], 
positive surgical margins [95], large tumour size [39], extensive tumour necrosis [96], 
concomitant CIS [97] and variant histology [55, 98] are reported to be predictors of 
poor survival outcomes after RNU.  
1.6.6 Bladder recurrence  
Intra vesical recurrence (IVR) after RNU has been described to occur in about 30% of 
the cases with a median time to recurrence of 22 months. A meta-analysis reviewing 
18 published papers on the topic concluded that several patient, surgical and 
pathological factors were identified as independent risk factors for IVR [99]. A 
nomogram for the prediction of IVR has been published [100]. An association 
between diagnostic and/or therapeutic URS and IVR after RNU has been described. 
Two larger meta-analyses analysing data including several thousand patients, 
concluded that preoperative URS increases the risk of IVR, but does not impact 
survival outcomes [101, 102]. Two randomized controlled trials (RCT) have shown 
that a postoperative instillation of mitomycin or pirarubicin to the bladder after RNU 
reduces the risk of IVR by about 30%, and is considered standard treatment according 
to guidelines [25, 103, 104].   
1.6.7 Prognostic models  
Several models for prediction of survival after RNU using postoperative factors are 
available [62, 105, 106]. Most published models include age, pT-stage and nodal 
disease in their models, while tumour architecture, lymphovascular invasion and 
tumour grade are other factors frequently used in the presented models. Most models 
are presented as nomograms with accuracies in the range of 0.78-0.82.  Scoring 
systems have also been presented [107].  
1.7 Disease management 
1.7.1 Localized non-metastatic disease  
Localized UTUC is defined as urothelial carcinoma confined within the kidney pelvis 
or ureter, or with local tumour growth into the renal parenchyma, peripelvic or 
periureteric tissue. Regional spread into lymph nodes in the hilum, retroperitoneum or 
pelvic lymph nodes on the ipsilateral side can also be considered as localized 
disease.  Patients with localized disease can be treated with a curative intent.  
The standard treatment of localized UTUC is a RNU with complete excision of the 
ipsilateral bladder cuff. However, surgical removal of a kidney with some or all 
kidney function intact, will inevitably lead to a reduction of the total kidney function 
for the patient. Studies from the treatment of RCC where NSS have become 
increasingly common indicate that NSS can reduce the risk of cardiovascular events, 
reduce the risk of end-stage kidney failure, and even improve OS compared to 
standard radical nephrectomy during follow-up (FU) [108-110]. 
Early on, NSS for UTUC was reserved for patients where RNU was considered 
contraindicated due to solitary or functional solitary kidney, grave comorbidities, 
and/or high age. As increasing evidence showed that NSS for UTUC could be 
performed with comparable oncologic results as RNU, NSS in the treatment of 
UTUC gained popularity. Taking into consideration the demonstrated benefit in 
preserving kidney function, NSS is now part of the standard treatment for selected 
cases of localized UTUC, also among patients with normal contralateral kidney and 
without significant comorbidities [25].  
1.7.2 Nephron sparing surgery 
NSS for UTUC can be performed as a segmental ureter resection (SU), URS with 
tumour ablation or using a percutaneous access for tumour ablation.  
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Segmental ureter resection 
SU is most commonly performed as a distal ureter resection with primary 
ureteroneocystostomy in the case of distal ureteral tumours.  The procedure is 
traditionally performed as an open procedure [64], but robot assisted laparoscopic SU 
is also described with acceptable results [111]. A pelvic LND is feasible in the same 
procedure if indicated [112]. Before SU can be performed for UTUC, it is of great 
importance to rule out concomitant UTUC in the remaining ureter and kidney pelvis. 
Both CT and particularly URS have demonstrated a high sensitivity in ruling out 
UTUC in the remaining part of the upper urinary tract [30, 52]. 
Segmental ureter resection has in several publications demonstrated equivalent 
survival results compared to RNU with better preservation of kidney function [64, 
112, 113]. As a result of this, SU is now considered an optional standard treatment for 
low-risk UTUC in the distal ureter when feasible [25]. Regarding high-risk UTUC, 
the topic is more controversial. Data available for analysis is more limited, but most 
published studies suggest oncological results for SU are comparable to RNU also for 
high-risk tumours [63, 114-116]. SU is considered an optional treatment strategy 
among selected patients with high-risk UTUC. Ipsilateral recurrence rates after SU is 
reported to be 7% [115].  
URS with tumour ablation  
This treatment modality has the advantage over SU that it can potentially be used in 
the entire UUT, and not only in the distal ureter. Endoscopic tumour ablation can be 
achieved by electrocautery or by the use of different lasers [117-119]. Survival 
outcomes equivalent to RNU can be expected when using endoscopic tumour 
ablation for low-grade tumours. The KPR in larger published series have been 67-
83%, and recurrence rates 55-77% [118, 120, 121]. A more exhaustive discussion 
about this topic is done in the discussion part of this thesis.    
Percutaneous access with tumour ablation 
Percutaneous access to the kidney pelvis for UTUC treatment is achieved by the same 
procedure as pyelolithotripsy for the treatment of urinary calculus. Tumour ablation 
can be achieved by electrocautery or laser ablation. Percutaneous tumour ablation is 
used less frequently than URS ablation and available literature on the subject is 
limited. Published series indicate oncological results comparable to RNU when 
treating low-risk tumours [122].   
1.7.3 Radical nephroureterectomy 
Since the first descriptions of RNU in the treatment of UTUC was published in 1940 
[123], RNU has been the standard treatment for UTUC. Even though substantial 
developments have been made in the diagnostics and treatment of UTUC, open RNU 
still remains the gold standard treatment for high-risk UTUC [25].  
Open radical nephroureterectomy 
A radical RNU should be performed removing the entire kidney including the 
Gerota’s fascia and the entire ureter with surrounding ureteral fatty tissue including 
the intramural part of the ureter, with a complete excision of the ureteral ostium 
[124]. Care should be taken to minimize manipulation of the tumour, avoid tumour 
spillage, and limit the urine leakage as much as possible. After open RNU, the overall 
complication rate has been reported to be 8-17%, while major complications 
(Clavien-Dindo 3 or more) in a meta-analysis is reported to occur in 4% of the 
patients. The perioperative mortality is reported to be 0.7-1.1% [125, 126]. Per-
operative blood loss has been estimated to 250-500ml with 15-25% of the patients 
subsequently requiring blood transfusions. Hospital stay is typically 4-7 days [125, 
127].   
Minimal invasive radical nephroureterectomy  
A minimal invasive RNU can be performed as a purely laparoscopic 
nephroureterectomy, or as a robot assisted laparoscopic RNU. The first successful 
laparoscopic RNU was described by Clayman in 1991 [128]. Later, a robot assisted 
procedure has been described [129]. A template based LND is shown to be feasible in 
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the same procedure [130]. Retroperitoneal laparoscopic RNU has also been 
described, but is less used [131]. Studies on minimally invasive RNU have repeatedly 
reported lower blood loss, fewer patients in need for blood transfusions, and shorter 
hospital stays compared to open RNU [127, 132]. Regarding other complications, 
several studies and one meta-analysis have found a similar complication rate 
comparing minimal invasive RNU to open RNU [126, 132].  
Outcomes regarding recurrence and survival of minimal invasive RNU have been 
described as comparable to open RNU for localized tumours (pTa-T2) [129, 133-
135]. However, one RCT described poorer survival outcomes for patients with 
NOCD treated with laparoscopic RNU compared to open RNU [136]. This finding 
has also been described by later studies verifying that patients with pT3+ tumours 
have a poorer CSS if treated with laparoscopic RNU compared to open RNU [137, 
138]. An open RNU is recommended as standard treatment for clinically advanced 
stage UTUC [25]. Port-site metastasis has been reported to occur in 0-2.8% of the 
patients [139].  
1.7.4 Lymph node dissection 
A LND is a part of the standard treatment of bladder cancer, where a LND has shown 
both therapeutic and diagnostic efficacy, and is routinely performed in adjunct to 
radical cystectomy for muscle invasive BC [140]. Regarding UTUC, the topic is more 
controversial. The landing sites for regional metastases have been described [141, 
142]. Regarding tumours in the renal pelvis and upper ureter, 80-90% of metastatic 
regional lymph nodes can be removed using a template of the hilum and paracaval or 
paraaortic template. Regarding tumours in the lower ureter, 70-80% of pathological 
lymph nodes can be removed using an ipsilateral template similar to extended lymph 
node dissection used for BC. 
The risk of lymph node metastasis is strongly dependent upon tumour stage. While 
lymph node metastasis is uncommon in pTa-pT1 tumours (<5%), it is increasingly 
common in pT2+ tumours (15-40%), [91, 143]. A recent review of available literature 
has concluded that performing LND in muscle-invasive UTUC will increase CSS 
[144], and a template based LND for muscle-invasive UTUC is now recommended in 
current guidelines [25].   
1.7.5 Management of the ureteral ostium and bladder cuff 
Complete resection of the intramural part of the ureter including the ureteral orifice 
has been shown to reduce the risk of later intravesical recurrence compared to 
incomplete resection, and is a mandatory part of RNU according to current guidelines 
[25, 99, 145]. Several methods for bladder cuff management have been suggested 
including intravesical and extravesical approaches, stripping, intussusception and 
transurethral techniques. None have convincingly shown to be superior to other 
methods as long as a complete resection is performed [146, 147].  
1.7.6 Local instillation treatment in the upper urinary tract 
Instillation of Bacillus Calmette-Guerin is part of the standard treatment regimen for 
BC [148]. Postoperative instillation of intra vesical chemotherapy after transurethral 
resection of bladder tumours has been shown to prevent later bladder recurrence [148, 
149].  
The use of similar topical agents instilled in the UUT has been described in several 
papers. Due to great heterogeneity of the published patient series, it has been difficult 
to come to any conclusion regarding a potential effect on recurrence or survival. The 
papers differ regarding patient selection, agent used, methods for administration and 
outcome measures. A meta-analysis published in 2019 included 27 different studies 
on the subject. The conclusion was that no significant differences in recurrence rates, 
progression, CSS or OS could be demonstrated between different agents or different 
methods for instillation. The authors conclude that to date, the efficacy of 
endocavitary instillations in treating UTUC or preventing UTUC recurrence is yet to 
be proved [150].  
A novel method using a mitomycin containing slowly dissolvable gel applied via 
ureteral catheter directly to the kidney pelvis for low-grade UTUC has recently been 
presented in a phase 3 clinical trial [151]. Results are promising with a complete 
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response rate of 60%, but these need further verification before the method can be 
taken into clinical practice.   
1.7.7 Perioperative chemotherapy 
Neoadjuvant cisplatin based chemotherapy before radical cystectomy has in RCTs 
proved to improve long-term survival for BC patients and is part of the standard 
management of muscle-invasive BC [140]. Regarding UTUC, no RCTs assessing the 
potential benefits of chemotherapy in a neoadjuvant setting is available. The effect of 
neoadjuvant chemotherapy in down-staging UTUC and obtaining complete remission 
at final pathology after RNU has been demonstrated, and a survival benefit has also 
been described in a retrospective non-randomized study [152-154].  
Population based studies have suggested a moderate benefit in OS for patients treated 
with adjuvant chemotherapy after RNU compared to observation alone [155]. One 
recent RCT comparing the use of RNU + adjuvant chemotherapy with RNU only 
supported this finding. The patients treated with adjuvant chemotherapy in addition to 
RNU, had a significant lower recurrence rate than the patients treated with RNU only 
[156].  
1.7.8 Adjuvant Radiotherapy 
Studies have shown that radiotherapy used as adjuvant to surgery and/or 
chemotherapy have no significant impact on survival, and can be recommended only 
in very selected cases [157, 158]. 
1.8 Metastatic disease  
Metastatic UTUC is defined as metastasis of UTUC to distant organs or distant 
lymph nodes. Patients in this category can only rarely be cured, and the main goal in 
treatment is to prolong survival, optimize quality of life and provide the best available 
palliative care. Untreated, median OS for metastatic BC is 3-6 months [159]. The 
outcomes of metastatic UTUC are poor. Colla Ruvolu et al. described a 1-year OS of 
39.7% with a median survival of 9 months among patients with metastatic UTUC in 
the USA. Patients treated with chemotherapy and/or RNU demonstrated improved 
survival compared to non-treated patients [14].  
1.8.1 Radical nephroureterectomy  
Several observational studies have indicated a moderate but significant (10-14%) 
improved 3-year OS for patients treated with RNU with or without chemotherapy for 
metastatic UTUC [160, 161]. This benefit might be limited to patients with only one 
metastatic site [162]. The evidence for the potential benefit of RNU for this patient 
group is limited, and the timing of the procedure (before or after chemotherapy) has 
not been studied. RNU can be an option for selected metastatic UTUC patients.  
1.8.2 Metastasectomy 
Metastatic urothelial cancer is generally regarded as a systemic disease where surgery 
has a very limited role in patient treatment. However, some patient series on 
metastasectomy for urothelial cancer both from BC and UTUC have been published. 
It seems that a minority (15%) of the patients can experience long-term survival after 
metastasectomy, primarily after resection of metastases in the lungs and lymph nodes 
[163, 164]. Metastasectomy can be regarded as an optional treatment for a highly 
selected group of patients.   
1.8.3 Chemotherapy 
As a result of early studies on metastatic BC, and later subsequent RCTs on 
metastatic BC with sub-analyses regarding UTUC, cisplatin based chemotherapy is 
regarded as first line treatment for metastatic UTUC [165-167]. A survival benefit of 
12-14 months in OS can be expected compared to observation. Studies on metastatic 
BC shows that carboplatin based regimens are inferior to cisplatin based regimens 
regarding survival [168]. Still, an objective response rate of 30-42% can be expected 
when treating metastatic UTUC patients unfit for cisplatin with carboplatin based 
regimens [169]. An objective response rate of 22-24% can be expected for vinflunine 





Immune checkpoint inhibitors have emerged as an attractive treatment option in 
many fields of cancer treatment in recent years, including urothelial cancer [25].  
Both the programmed cell death protein inhibitor pembrolizumab and the 
programmed death ligand inhibitor atezolizumab have been tested as first line 
treatment for cisplatin ineligible patients in phase II studies for metastatic urothelial 
cancer. Post-hoc analyses of metastatic UTUC patients in these studies have shown 
similar response rates for metastatic UTUC patients compared to patients with 
metastatic BC. The objective response rate was 23-29% with a complete response 
rate of 7-9%. The toxicity profiles were favourable for both regimens [171, 172]. On 
the basis of these findings, both these drugs are approved as first line treatment for 
programmed death ligand inhibitor positive patients with metastatic BC patients 
ineligible for cisplatin based therapy. Both pembrolizumab and atezolizumab and 
have shown objective response rates from 21-26% as second line treatment for 
metastatic urothelial cancer relapse after treatment with cisplatin based regimens, and 
are considered viable options for metastatic UTUC patients in these categories [173, 
174].  
1.9 Follow-up 
To the best of our knowledge, no publications dedicated solely to the evaluation of 
FU regimens after treatment for UTUC are presented. As a result, all 
recommendations in guidelines are recommendations based on standard practice and 
expert opinions.   
The aims of FU after RNU are the detection of IVR and metastatic disease after 
RNU. IVR after RNU is frequent, and cystoscopy should be performed regularly. In 
current guidelines, cystoscopy is recommended after three months, and then at set 
intervals for five years depending on the risk of recurrence. The risk of recurrence 
should be taken into account when deciding intervals for cystoscopy. The risk of 
metastatic disease after RNU is considerable, but also strongly dependent upon 
several factors as described previously. However, the potential benefit for the patient 
in detecting metastasis in a pre-symptomatic phase is debatable. If a patient is fit for 
available treatment (chemotherapy and/or immune checkpoint inhibitors) for 
metastatic disease, a CTU should be performed regularly. According to guidelines, a 
CTU every 6 months for two years and then yearly is recommended for high-risk 
patients.  
In FU after NSS, a risk of ipsilateral recurrence exists in addition to the risk of IVR 
and metastatic disease. Regarding FU after endoscopic treatment, the authors of 
published series on this topic recommend a rigorous FU since the recurrence rates 
after this treatment modality are high. Scotland et al. recommend URS surveillance 
every 3 months until the patient is considered tumour free, and then URS every six 
months [118]. It was not stated how long this surveillance program should continue, 
or whether a CTU could replace the URS in the later FU.  
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2. Aims of the thesis 
There is a paucity of high-quality studies regarding UTUC, and a considerable 
knowledge gap concerning several aspects of the disease. Basic epidemiologic 
knowledge about the current incidence and possible changes over time in Norway and 
Europe is lacking. Despite its relative rarity, the diagnostic work up and treatment 
possibilities of UTUC have changed substantially in the last decades. Proper 
preoperative staging to tailor the right treatment for any given patient is one of the 
main challenges in UTUC treatment today. The use of NSS in the treatment of UTUC 
has become more common, but the indications for these treatment options are not 
fully understood.    
The main aim of the present thesis was to improve our understanding of the 
epidemiology, diagnostic work-up and treatment of UTUC. Fig 3 illustrates how the 
different parts of the thesis stand together to create an entity.  
 
 
Figure 3. Illustrates how the different elements of the thesis are integrated as a 
whole. As demonstrated, the ultimate goal is to improve UTUC patient treatment. 
Paper 1 
The aim of paper 1 was to obtain contemporary knowledge about UTUC incidence 
including incidence relative to other urothelial cancers and RCC in Norway. Further 
to look for and analyse possible changes over time regarding UTUC incidence, 
patient demographic variables, and tumour characteristics.  
Paper 2 
The aim of paper 2 was to evaluate standard preoperative staging with CT and URS 
when done before RNU to see if our staging is adequate to select patients for the right 
treatment modality. Specifically we evaluated all registered preoperative variables 
regarding the patient, the CT scan, URS and cytology and analysed their respective 
abilities to predict NOCD at final pathology, and survival after RNU.  
Paper 3 
The aim of paper 3 was to perform an external validation of a previously published 
diagnostic model [54] generated to predict non-organ confined UTUC at final 
histopathological examination after RNU.  
Paper 4 
The aim of paper 4 was to evaluate endoscopic treatment given at our hospital during 
2001-2012, with focus on outcome measures stratified by treatment groups and 




3. Materials and methods 
3.1 Permissions and ethical considerations 
Regarding paper number 1, scientific studies performed at the NCR are exempt from 
the general rule that ethical approval from the regional ethics committee (REK) is 
necessary for scientific research in Norway. One of the purposes of the NCR is to 
facilitate scientific research. Regarding paper number 2 and 3, ethical approval of the 
studies was obtained from REK (reference no. 2017/854 and 2017/930). Regarding 
paper number 4, ethical approval from the REK was not necessary, as the study was a 
purely retrospective single centre study assessing a treatment already given. Prior to 
collection and storage of data, approval of this study was obtained from the internal 
review board at Haukeland University Hospital.  
3.2 Study populations and methods 
Paper 1 
Regarding paper 1, the study population was gathered at the NCR. The NCR is 
nationwide, and has since 1953 kept a complete registry of all new cases of malignant 
neoplasms. All patients classified with ICD-10 diagnosis code C65 (cancer in the 
kidney pelvis) and C66 (cancer in the ureter) registered during 1999-2018 were 
inquired from the main database at NCR. From a total of over >1.900.000 cancer 
cases registered at the NCR, 3502 cases were extracted from the main database for 
evaluation. After an exclusion process, 406 cases were excluded due to uncertainty 
regarding the diagnosis (n= 334) or non-urothelial cancer (n=72), leaving 3096 cases 
with verified UTUC in 2818 patients for analysis in the study. All analyses were 
made according to the number of cases. The database included information about e.g. 
patient sex, age at diagnosis, date of birth, histopathological data, clinical data ( 
cancer report, death report etc.), treatment and current status (deceased or alive). 
One of the aims of the study was to compare UTUC incidence with the incidence of 
other urothelial cancers and RCC. Additional extractions were made regarding cases 
with diagnosis code C67 (BC), C68 (Urethral cancer) and C64 (RCC) during 1999-
2018. After an exclusion process resembling the one used for UTUC patients, 24467 
cases of BC, 287 cases of urethral cancer, and 13619 cases of RCC were included in 
the study.   
Paper 2 and 3 
The medical records of 209 patients treated with a RNU between 2005 and 2017 for 
suspected UTUC at Haukeland University Hospital (n=130) and the Vestfold 
Hospital Trust (n=79), were retrospectively examined. 30 patients were excluded, 15 
of these due to non-urothelial cancer (most of them RCC), nine due to concomitant 
bladder cancer with cystectomy in the same procedure as RNU, and six because no 
viable cancer was present at the final histopathological specimen after RNU, leaving 
179 patients for evaluation.  
Patient age, sex, comorbidities, kidney function, presenting symptoms and smoking 
status were registered together with the presence of prior bladder cancer or prior 
endoscopic treatment for UTUC. 176 patients were examined with a CT scan, 159 of 
these with i.v. contrast. All CT scans were re-examined and evaluated regarding 
tumour location, size, contrast enhancement, the presence of reactive oedema 
surrounding the tumour, hydronephrosis and local invasion into the renal 
parenchyma, the peripelvic or periureteric tissue. 95 patients were examined with a 
diagnostic URS with biopsy and 60 patients had a cytology taken. Data regarding 
tumour location, stage and grade were gathered from the pathology reports at the 
respective institutions. Tumours were graded according to the two-tiered WHO 2004 
classification and staged according to TNM 2017 classification. All specimens 
originally not concurring with these two classifications were re-examined and 
reclassified by uropathologists (OJH and BC). 
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For paper 3, histological tumour grade and gross architecture from the final pathology 
report were registered and used together with the variables already registered and 
used for paper 2.  
Paper 4  
The medical journals of 140 patients treated surgically for UTUC at Haukeland 
University Hospital during 2001-2012 were retrospectively examined. 90 of these 
were treated with a RNU, seven with a SU, and 43 endoscopically with a curative 
intent. These 43 were all considered to be potential candidates for endoscopic 
treatment after initial radiological imaging. A URS was then performed and biopsies 
were taken when possible. Endoscopic treatment was given in the same procedure if 
it seemed feasible. The patients were treated with either URS (n=34) or with 
percutaneous nephroscopy (n=9). The URS were performed using either a semi-rigid 
or a flexible ureteroscope, while the percutaneous nephroscopy was performed using 
a rigid nephroscope. Tumour destruction was performed using a YAG-Holmium laser 
or electrofulguration.   
All relevant demographic information about the patients was registered. After 
finishing the inclusion of patients, all the initial biopsy specimens were re-examined 
by a uropathologist (OJH) and graded in accordance with the three-tiered WHO 1973 
system (grades 1, 2 and 3), and the two-tiered WHO/ISUP 2004 system (low- and 
high-grade). A complete histopathological evaluation from the biopsies was possible 
in 40 of 43 patients (93%). 
The patients were divided into groups for the purpose of analysis. Firstly, the patients 
were divided into two groups according to indication for endoscopic treatment. 
Patients with an elective indication were placed in the candidates for 
nephroureterectomy (CNU) group, while patients considered not fit for RNU due to 
comorbidities and/or high age were placed in non-candidates for nephroureterectomy 
(NCNU) group. Secondly, the patients were divided into groups according to tumour 
grade, one low-grade, and one high-grade group.  
3.3 Statistical analysis 
All papers 
Databases for the study populations of the respective studies were generated using 
IBM® SPSS® statistical software versions 21-26 according to publication date and 
version available at the time the work was done.  
• Differences between groups regarding continuous variables were analysed 
using a Student's t-test  
• Differences between groups regarding categorical variables were analysed 
using a chi-square test  
• Survival, recurrence and kidney preservation estimates were calculated using 
the Kaplan-Meier method, and a log rank test was used when comparing 
groups  
• P–values less than 0.05 were considered statistically significant for all tests 
Paper 1 
Crude incidences of UTUC were calculated for each year (1999-2018) using 
population data for Norway from Statistics Norway the corresponding year [175]. 
Crude incidences for each 5-year age interval for each year were calculated to 
facilitate population adjustment. The population adjustment was then performed 
using the updated European standard population (2013) as the main reference [176]. 
Both crude incidences and ASR according to the European standard population were 
presented in the paper. For purposes of changes over time analysis and presentation, 
the material was split into 5-year periods (1999-2003, 2004-2008, 2009-2013 and 
2014-2018). The relative proportion of UTUC cases compared to all urothelial cancer 
cases and pelvic urothelial tumours compared to RCC cases were calculated for each 
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5-year period. Analyses regarding changes in patient age, sex distribution and 
location of the tumour were performed in the same manner. The five-year periods 
were compared using the chi-square method, and for further analyses of changes over 
time, linear regression analyses were made calculating yearly changes and assessing 
statistical significance. Survival estimates for the 5, 10 and 15 year OS and CSS were 
calculated using the Kaplan–Meier method, and a log-rank test was used to compare 
groups.  
Paper 2 
For prediction of tumour stage at final histopathological examination after RNU, all 
candidate variables regarding patient features, CT and ureteroscopic findings were 
analysed using univariate and multivariate logistic regression analysis to assess their 
abilities to NOCD. Survival estimates for the 5- and 10 year OS and CSS were 
calculated using the Kaplan–Meier method, and a log-rank test was used to compare 
groups. Furthermore, multivariate cox regression analyses including both patient 
features and final histopathology were performed to evaluate independent predictors 
of all-cause and cancer-specific mortality. For the comparison of groups, continuous 
and categorical variables were analysed using a Student’s t-test and a chi-square test, 
respectively.  
Paper 3 
The external validation was performed according to principles described by Altman 
et al. to include both model calibration and discrimination [177]. Each patient in our 
cohort was allocated points from the nomogram corresponding to tumour grade, 
location and architecture. The total score was evaluated using the Margulis 
nomogram to determine the predicted risk of NOCD for each patient. This was 
compared to the true observed risk of NOCD seen in the cohort. Comparisons 
between predicted and observed risk were made to assess model calibration and the 
results were graphically explored in a scatterplot. Reliability analysis to assess 
interclass correlation between observed and predicted risks was performed using 
Cronbach alpha measurement. The predictive accuracy of the Margulis model and the 
present model was assessed by calculating the area under curve (AUC) in a Receiver 
Operating Characteristic (ROC) model. Model discrimination was assessed 
comparing the AUC from the Margulis model and the present model.  
Paper 4 
Differences between the patient groups and tumour grade groups were assessed using 
Student’s t-test, and chi-square tests. Survival and recurrence estimates were made 
using the Kaplan-Meier method, and a log-rank test was used to compare 
groups.  Predictors for survival, recurrence and KPR were further analysed using uni- 




4. Summary of results 
Paper 1 
The crude incidence of UTUC in the whole time period was 3.17:100.000, increasing 
significantly from 2.54 to 3.98 from the first to the last five-year period. The ASR 
according to the European standard population was 3.88 for the whole period, 
increasing significantly from 3.21 to 4.70 from the first to last five-year period. The 
population adjusted estimated annual increase in incidence was 0.10 (CI 0.06-0.13, 
p<0.001), corresponding to an average annual increase of 2.5%.   
UTUC incidence increased significantly for all age groups (decades) over 60 years of 
age. The mean age at diagnosis increased significantly from 71.8 to 73.9 years from 
the first to the last five-year period. The proportion of UTUC of all urothelial cancers 
also increased over time, and constituted 12.6% in Norway during 2014-2018. Of 
3096 cases, 1811 (58.5%) were located in the renal pelvis. The proportion of 
urothelial cancers in the renal pelvis increased over time, and constituted 12.9% of all 
renal tumours in Norway during 2014-2018.  
We found a 5, 10 and 15-year OS of 47.7%, 32.7% and 22% respectively. The 5, 10 
and 15-year CSS was 75.3%, 72.9% and 70.8% respectively. OS improved over time, 
comparing the last decade with the first (five-year OS 44.3% vs 51.7%, p=0.003). No 
differences were found in survival regarding gender or tumour location.  
Paper 2 
Local invasion and pathological lymph nodes at CT predicted NOCD in uni- and 
multivariate regression analyses (OR 3.36, p=0.004 and OR 6.21, p=0.03, 
respectively). Fatty tissue reaction surrounding the tumour (OR 2.55, p=0.02), tumour 
size (4.8 vs. 3.9 cm, p=0.006) and histological high-grade tumour at URS biopsy (OR 
3.59, p=0.04) predicted NOCD at univariate regression analyses. No patient variable 
was found to predict NOCD in the present cohort. The five-year CSS and OS for the 
entire cohort was 79% and 60%. Only the pathological tumour stage (at final 
pathology after RNU) predicted CSS at multivariate analysis. Histological evaluation 
of the URS biopsy could verify the diagnosis in 66/95 (69%) of the cases. 12 of 34 
(35%) low-grade tumours at biopsy were upgraded to high-grade at final pathology 
after RNU. Local invasion at CT was found to be the best suited variable to consider 
when selecting patients for intensified treatment.  
Paper 3 
A comparison between the Margulis cohort and our cohort regarding patients and 
tumour characteristics was made. The patients in our cohort more often presented 
with local symptoms (74% vs 61%, p=0.01), a larger proportion had Eastern 
Cooperative oncology Group score of ≥1 (48% vs 37%, p=0.01), a higher proportion 
of the tumours were high-grade by histology (75% vs 60%, p<0.001) and a higher 
proportion of the tumours had a sessile architecture upon gross pathological 
examination of the surgical specimen (34% vs 25%, p=0.02).  
Tumour grade and tumour architecture were significant predictors of NOCD on final 
pathology at multivariate regression analysis (OR 28, p=0.001, and OR 4.7, p<0.001 
respectively). Tumours in the renal pelvis had a higher occurrence of NOCD 
compared to tumours in the ureter in the present cohort, but in contrast to the cohort 
of Margulis et al., the difference was not statistically significant in our cohort (OR 
1.5, p=0.4). 




Overall concordance between predicted and observed risk was high, quantified as a 
Cronbach Alpha of 0.96. The scatterplot indicates some mis-calibration of the model 
at low risk levels. The AUCs of both the predicted and observed risks in predicting 
NOCD in a ROC model were 0.83 (95% CI 0.77 -0.89), indicating that predicted and 
observed risk discriminated equally well between patients with low- and high risk for 
NOCD. The overall predictive performance was high, and we considered the 
Margulis nomogram validated for clinical use. 
Paper 4 
The 43 primary endoscopic treatment procedures were followed by 69 later 
treatments, and 77 follow-up procedures without treatment.  Mean (median) number 
of procedures per patient was 4.72 (3), with a range of 1-12. 
Comparing the CNU and the NCNU groups, the patients in the NCNU group were 
significantly older (77 vs 70 years, p=0.003), had a higher comorbidity when 
comparing Charlson comorbidity index (p=0.005), and a poorer kidney function 
(eGFR 92 vs 66 ml/min, p= 0.003). OS (71% vs 25%, p<0.001) and Disease specific 
survival (DSS), (94% vs 41%, p<0.001) were significantly higher in the CNU group 
 Figure 4. Illustrates the 
concordance between observed 
in the cohort and predicted 
risk according to the Margulis 
nomogram. The overall 
concordance was high, 
quantified as a Cronbach Alfa 
of 0.96.  
compared to the NCNU group. Survival data stratified by grade is demonstrated in 
figure 5.   
 
Figure 5. Disease specific survival (DSS) stratified by histological grade according 
to WHO/ISUP 2004 and WHO 1973. The grey lines show DSS among patients with 
G1, G2 and G3 tumours according to WHO 1973. The black lines show DSS among 
patients with low-grade and high-grade tumours according to WHO/ISUP 2004. The 
difference in DSS between the WHO/ISUP 2004 low-grade tumours and high-grade 
tumours was statistically significant (p=0.001).  
Patients with low-grade tumours had a higher DSS (96% vs 39%, p<0.001) and OS 
(75% vs 23%, p<0.001) compared to patients with high-grade tumours. In multivariate 
analyses, age was the only significant predictor for OS, and tumour grade was the only 
significant predictor for DSS.  
25 of 43 (58%) of the patients became tumour free at one point during FU after 
endoscopic treatment. Patients were regarded as tumour free only after a negative 
URS was performed. Among these patients the five-year recurrence free survival was 
76%.  
In the CNU group, 14 of 28 patients experienced perceived progressions and a RNU 
was performed.  The five-year KPR was 51%. The KPR among patients with low-
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grade tumours was 60%. Four of the RNU specimens were pT0 with no viable 
tumour tissue at final histopathological evaluation after RNU, and those four all had 
low-grade tumour from a prior endoscopic biopsy.  
Among 14 patients regarded as tumour free at first endoscopic follow-up, only two 
had a later RNU. The patients deemed tumour free at first follow-up had a five-year 
KPR of 90%. In a multivariate regression analysis, an absence of tumour at the first 
follow-up URS was a significant predictor of KPR. 
5. Discussion 
5.1 On the epidemiology of UTUC 
5.1.1 Background 
In paper 1, we described an increasing incidence of UTUC. The ASR in Norway is 
presently at 4.7:100.000 during 2014-2018. UTUC currently constitutes close to 13% 
of all UC in Norway. Together with the recent Dutch study [13], this is the highest 
UTUC incidence reported outside endemic areas.  
The results of previous studies on the topic are somewhat contradictory, as is 
described in the introduction part of this thesis. It is not easy to get a clear insight into 
the current incidence of UTUC and changes over time from these publications. The 
analysed populations come from different parts of the world and are drawn from 
different time periods. The inclusion criteria are different, and the population 
adjustments are performed according to different standard populations. The general 
impression from these studies however, was a lower UTUC incidence than we 
described in the present study, and more in line with the commonly quoted incidence 
of 1-2:100.000.   
5.1.2 Changing incidence and possible explanations 
An incidence rate of 1-2:100.000 should result in ~55-110 new cases of UTUC every 
year in Norway. Contrary to this estimate, an average of 208 yearly cases the last five 
years were found. This corresponds to a crude rate of 3.98, and an ASR of 4.70 
adjusted to the 2013 version of the European standard population. The increase in the 
ASR over the last 20 years has been at an average of ~2.5%, resulting in an 80% 
increase in UTUC cases in the time period.  
 
A comparable increase in incidence was described in the recent study by Van 
Doeveren et al. [13]. They described a 50% increase in ASR (adjusted to the 1976 
version of the European standard population) from 2.0 to 3.2 from 1993-2017 using a 
cohort of more than 13.000 cases. These incidence rates are actually higher than the 
rates we reported. Adjusted to this older version of the European standard population, 
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we found an increase in UTUC incidence from 2.0-2.7 during 1999-2018 in our 
cohort (the details are available in supplementary table 2 in the paper published). A 
considerable increase in incidence to a higher level than previously described is thus 
the finding in two recent European publications based on national population based 
cohorts. Contrary to this, a recent study based on the American SEER database found 
a decreasing incidence in the USA from 1.3-1.1 adjusted to the American standard 
population from 2000 [14]. This latter study is hampered by the fact that Ta/CIS 
tumours were not included in the version of the SEER database used, and will thus 
underestimate total UTUC incidence. In a previously quoted more historical study 
also using the SEER database, an increasing incidence of in situ (Ta/CIS) tumours to 
31% of total was reported in the USA 1997-2005 [9]. It is thus probable that the 
underestimation of UTUC incidence in the study from Colla Ruvolo et al. is 
substantial.  
 
It seems clear that the incidence of UTUC in Europe is rising, but the reasons for the 
demonstrated increase is not clear. One possible reason could be that older patients 
are more thoroughly examined for symptoms presently compared to earlier. The last 
two decades the access to high quality CT and flexible ureterrenoscopes have 
improved significantly. Older patients are also more often in better physical shape 
and could be candidates for a RNU at a high age in case a high-risk UTUC was found 
at diagnostic work up of e.g. haematuria. An increased effort in examining symptoms 
would increase the detection rate of UTUC and result in higher reported incidences.  
 
One potential effect of increased diagnostic work up among the elderly could be an 
increased mean age at diagnosis. This fits well with our findings. There has been an 
absolute increase in cases over 80 years at diagnosis from 115 to 303 cases, (263%) 
from the first to last five-year period. The proportion of patients >80 years of age at 
diagnosis increased from 21% to 29%. This increase is the main reason why the mean 
age at diagnosis has increased from 71.8 to 73.9 during the study period. One might 
speculate that such increased diagnostics should result in a stage migration toward 
lower tumour stage at diagnosis in the latest periods. We do not have firm evidence of 
this in our cohort as data on staging is not complete. There are however some 
indications that this might be so. The proportion of invasive vs non-invasive tumours 
decreased non-significantly (50% to 41%, p=0.07) during the study period, while 
survival improved. At the same time, diagnoses verified by biopsy without following 
surgery increased from 11% to 24% and the use of conventional radical surgeries 
declined. The decrease in radical surgeries might be because more patients got a 
diagnosis without following treatment, but it could also be due to increased use of 
endoscopic treatment, as this is not registered as radical surgeries at the NCR. 
Increased examination of symptoms and an increased detection rate among the 
elderly seems like a probable cause of increased UTUC incidence, but the magnitude 
of such an effect would be difficult to measure exactly. Further examination into this 
possible effect could be the scope of future research on the topic. 
 
It is also possible that there is a true increase in the UTUC incidence in the 
Norwegian population, and not just an increased detection rate. The main established 
risk factors for UTUC are smoking, alcohol consumption and exposure to aristolochic 
acid [25]. There has been a decline in smoking in Norway, but the reduction in 
smoking among the elderly is smaller than for other age groups [175]. Even though 
the number of current smokers has declined over the years, the total number of 
current or previous smokers has probably risen over the time period. It is possible that 
a larger proportion of people over 70 years of age have been exposed to cigarette 
smoking presently compared to earlier, and could be an explanation to increased 
UTUC incidence. Specific data on the individual alcohol consumption and exposure 
of aristolochic acid in the Norwegian population is limited. Further discussion about 
this topic is beyond the scope of this thesis.  
 
Survival 
Publications describing changing UTUC survival over time are limited. The largest 
cohorts available present the survival outcomes after radical treatments as a snapshot, 
and do not analyse possible changes in survival over time. Eylert et al. found a five 
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year survival rate 48%, decreasing over time. Woodford et al. described a stable but 
low five year CSS of 32%. In our cohort we found a five-year OS and CSS of 61% 
and 48% respectively. A non-invasive tumour, lower age, and radical treatment were 
indicators of better survival, as can be expected. The described survival from the 
NCR cohort is poorer than the survival described in the cohort user for paper 2 and 3, 
where a CSS of 79% and OS 60% was found. This is probably because the NCR 
cohort includes all UTUC patients, and not just patients treated with RNU. Survival 
improved moderately over time. This could be due to a stage migration, although 
there is no firm evidence for this in our cohort. Gender and tumour location did not 
predict survival in our cohort. Since an accurate description of tumour stage and 
treatments given is not available in our data, further in-depth analyses regarding 
survival is not meaningful.  
5.1.3 Epidemiological variables 
There are no evident changes in the distribution of new cases according to gender or 
anatomical location. A majority (61%-77%) of the patients are reported to be men, 
well in line with our findings, with no signs of changes over time. Likewise, a 
majority of the tumours (51%-66%) are located in the kidney pelvis, also in line with 
our findings, with no significant changes over time. Mean age however, has been 
reported to be increasing. Both Raman et al. and Eylert et al. described an increased 
age at diagnosis from 68 to 73 years [8, 9]. This corresponds well with our findings of 
an increased age from 71.8 to 73.9 years during the study period. In the recent Dutch 
study, an increased age at diagnosis from 70 to 72 years was reported [13].  
5.1.4 Implications 
These findings could have several possible implications. An increasing number of 
UTUC patients would mean that more resources for diagnostics, treatment, follow-up 
and research should be allocated to this patient group.  Another implication could be 
recruitment into studies. Enrolment into studies could be quicker than expected, 
making studies on UTUC with adequate patient numbers easier to conduct.  
 
5.2 On the diagnostic work-up of UTUC 
Paper 1 described the incidence and demographics of the patient pool of UTUC we 
meet as clinicians. We will now move on to discuss the diagnostic work up of these 
patients. The diagnostic work up of patients presenting with symptoms potentially 
caused by UTUC serves two purposes. Firstly, the purpose is to establish the correct 
diagnosis – in this case to verify if the patient has UTUC or not. The second purpose 
is to provide information about tumour characteristics and stage, so that the clinician 
can choose the appropriate treatment for the diagnosis. 
5.2.1  Setting the correct diagnosis 
According to current guidelines, a CTU together with a cystoscopy is standard 
diagnostic work-up for a patient presenting with symptoms potentially due to UTUC. 
The sensitivity and specificity of multi-detector CTU to detect UTUC has in a meta-
analysis been found to be >90% [30]. In a study by Commander et al. including 1123 
patients, no further cases of UTUC were detected during a FU of three to ten years 
after a negative CTU, indicating a very low false negative rate [178]. The high 
specificity might lead to the conclusion that CTU is sufficient diagnostic work-up in 
most cases, since the false positive rate is below 10%. Other studies have however 
described a lower specificity. A prospective Swedish study including 174 patients 
found a sensitivity and specificity of high-quality multi detector CTU of 89% and 
51% respectively in detecting UTUC [52]. In this study all patients were examined 
with a diagnostic URS regardless of the result of the CTU. The low specificity of 
51% was due to overestimation of a possible tumour at CTU, as a following 
examination with URS including cytology and biopsy in many cases ruled out a 
tumour. The false negatives in that study were due to cases of CIS not detected at 
CTU. An Israeli study found that the rate of misdiagnosis at RNU dropped from 15% 
to 2.2% after the introduction of routine URS in the preoperative diagnostics at their 
department [178]. Current guidelines recommend the use of a diagnostic URS if the 
findings at the CTU and cytology is not sufficient to set the diagnosis or to risk 
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stratify the tumour [25]. To conclude, current evidence shows that the sensitivity of 
the CTU is high, so the risk of missing tumours when the CTU is negative is low. The 
exception to this general rule is cases where cytology shows CIS, as this tumour can 
be hard to detect on CTU. These patients should be followed-up with a URS and/or 
repeat imaging. If the CTU is inconclusive, there is a need to examine further with 
URS to verify or rule out a malignant tumour in the UUT. 
5.2.2  UTUC staging 
Background  
The accurate preoperative staging of UTUC is more challenging than setting the 
correct diagnosis. The issue has been studied by several groups, and factors from 
radiology and the URS have been described as predictors of tumour stage, as 
described in the introduction part of this thesis. Since staging using a single feature 
can be challenging, diagnostic models have been developed. None of these models 
have until now been subject to external validation. 
The ability to preoperatively stage the tumour as accurately as possible is important 
for several reasons. A low-stage and low-grade tumour can be a good candidate for 
NSS, while a more advanced tumour could be a candidate for intensified treatment 
such as perioperative chemotherapy and/or extended LND. There is also evidence 
that non-organ confined tumours (pT3+) should be treated with an open RNU, while 
localized (pTa-T2) could be treated safely with a laparoscopic or robot assisted RNU 
[133, 135]. The benefit of intensified treatment for advanced cases of UTUC has been 
demonstrated in several papers. However, there are also potential negative side 
effects of these treatments, such as toxicity regarding chemotherapy and potential 
morbidity for the extended LND. The indication for intensified treatment should be 
considered closely, and current evidence suggests that it should be reserved for 
advanced cases of UTUC, underscoring the importance of accurate preoperative 
staging. 
5.2.3  Evidence gap and background for our studies 
Despite advances in radiology, endoscopy and the developments of diagnostic 
models, the clinician still often faces difficulties in deciding the optimal treatment for 
a given UTUC patient. It is clear that a knowledge gap exists on this issue. As a result 
of this, we decided to evaluate the preoperative staging and diagnostic work-up 
regarding our UTUC patients, and evaluate if our findings could help elucidate a 
difficult topic. In paper 2 we evaluated the standard diagnostic work-up before RNU 
to identify predictors of tumour stage and prognosis. In the following section we will 
discuss our specific findings described in paper 2 in context of existing literature with 
special emphasis on selection of patients for intensified treatment in addition to 
conventional RNU. Intensified treatment in this setting means the use of perioperative 
chemotherapy or the use of extended LND at RNU. Further we will discuss our 
findings in paper 3 in relation to the use of diagnostic models.   
5.2.4  Prediction of tumour stage 
Patient factors 
No patient factors were found to predict NOCD in our cohort. Several patient factors 
have been described as predictors of outcome, but these have to our knowledge not 
been analysed regarding the prediction of tumour stage. Poor performance status, 
high age, or reduced kidney function could of course make the patient unfit for 
perioperative chemotherapy, but to date, no patient factors have been identified that 
could aid the clinician in the selection of patients for intensified treatment. 
The diagnostic URS 
The indication for the diagnostic URS in case the CTU is inconclusive, or if the 
patient is a candidate for NSS, seems well established. When it comes to the staging 
of UTUC among patients with an established indication for RNU, the usefulness of 
the diagnostic URS is more debatable.  
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In our cohort, a diagnostic URS with biopsy was performed in 95 patients. In 66 
(69%) of the patients, the biopsy could be used to confirm UTUC diagnosis, and in 
57 (60%) the biopsy material was sufficient to determine histological tumour grade. 
12 of 34 (35%) of low-grade tumours at biopsy were upgraded to high-grade at final 
pathology after RNU. The diagnostic accuracy in our study might seem unacceptably 
low, but both the diagnostic yield and the rate of upgrading are in line with the 
findings of other authors [46]. We found in our study that the presence of a high-
grade tumour at biopsy predicted NOCD (OR 3.59, p=0.04). The sensitivity and 
specificity of high-grade biopsy to predict NOCD was 63% and 68% respectively. 
The predictive ability of high-grade biopsy has also been evaluated by Brien et al. 
and Favaretto et al. Brien et al. found a sensitivity and specificity of 59% and 70% of 
high grade biopsy to predict MID. Both groups further described that high-grade 
biopsy predicted NOCD with an OR of 3.7-3.9 [38, 53]. 
 When considering the indication for a URS, it is important to remember potential 
negative side effects of the procedure. Two meta-analyses have shown an increased 
risk of post RNU bladder recurrence among patients examined with diagnostic URS 
prior to RNU [101, 102]. In addition to this, the URS would take time and resources, 
and cause delay in definite treatment. 
The predictive ability of histological tumour grade and cytology to predict NOCD is 
demonstrated both in our cohort and by other authors. The question is how this 
information can be used in clinical practice. The described sensitivity and specificity 
in the range of 60-70% in predicting NOCD is in our opinion too low to be clinically 
useful when selecting patients for intensified treatment. We conclude that the 
diagnostic URS as a staging procedure for selecting patients for intensified treatment 
is of limited worth, as the results only rarely will impact treatment choice. The 
method has considerable limitations, and there are possible negative side effects of 
the procedure. We argue that the diagnostic URS in most cases could be omitted 
when a decision to perform a RNU has already been made. 
Cytology 
In our cohort, a cytology sample was taken in 60 patients, 43 of these taken during 
URS. Malignant cells were detected among 37 (62%) of these. Positive cytology by 
the finding of malignant cells did not predict NOCD in the present material. In the 
cohort of Brien et al. a positive cytology was found in 80% of the patients, and the 
presence of a positive cytology was found to be a significant predictor of NOCD. 
Despite the findings of Brien et al., we argue that the predictive abilities of a positive 
cytology is not well enough documented for it to be used as a factor when 
considering a patient for intensified treatment.  
CT Urography 
Multi detector CTU has been described as superior to conventional CTU and other 
CT modalities in tumour staging, and should be the method of choice, especially in 
cases where there is doubt about the diagnosis or staging [52]. 
Hydronephrosis: Hydronephrosis was present among 65% of the patients in our 
cohort, and was not found to be a predictor of NOCD. There are conflicting results in 
the literature about whether the presence of hydronephrosis predicts advanced stage 
UTUC. Several authors have reported that hydronephrosis is an independent risk 
factor for NOCD [31, 32]. Hydronephrosis as an adverse factor for tumour stage was 
included in the diagnostic models of both Favaretto et al. and Brien et al. Contrary to 
this, other authors have studied the same issue and have concluded that 
hydronephrosis is not a predictor for tumour stage, in line with our findings [33, 34]. 
As the results are contradictory, it does not seem that the presence of hydronephrosis 
is a suitable feature to use when deciding to use intensified treatment or not. 
Tumour size: In our cohort, we found that patients with NOCD had larger tumours 
(as measured at CT) than patients with organ confined disease (4.8cm vs 3.9cm, 
p=0.006). A similar conclusion was drawn by Shibing et al [39]. We found however, 
that it was difficult to set a specific cut-off point regarding tumour size, and we 
concluded that tumour size was not well suited as a parameter when selecting patients 
for intensified treatment. 
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 Fatty tissue reaction: During the re-examinations of the CT scans as part of the 
development of the database, we noticed a reaction in the fatty tissue surrounding 
many of the tumours. This is radiologically similar to the fatty tissue reaction you can 
see surrounding e.g. appendicitis or diverticulitis. This fatty tissue reaction was found 
to be a predictor of NOCD. This was particularly true regarding a sub analysis for 
ureteral tumours where this fatty tissue reaction predicted NOCD with an OR of 8.0, 
p=0.003. The sensitivity and specificity of this feature was 55% and 87% respectively 
(data not shown). This is potentially clinically meaningful, since NOCD was 
uncommon in the absence of fatty tissue reaction, with a NPV of 80%. One could 
hence argue that intensified could be omitted in absence of fatty tissue reaction. This 
is an interesting finding that to our knowledge has not been described before. 
However, its predictive abilities should be confirmed in further studies before it is 
taken into clinical use. 
Pathological lymph nodes: The presence of pathological lymph nodes at the 
preoperative CT scan was in the present cohort found to be a significant predictor of 
NOCD in multivariate analysis (OR 3.36, p=0.004). Its predictive abilities have been 
reported by other authors [179]. The sensitivity and specificity in predicting NOCD 
was 22% and 98% respectively. This high specificity is clinically useful since the risk 
of “over-treating” a patient with non-muscle invasive disease in case of pathological 
lymph nodes disease is very low. The presence of pathological lymph nodes could be 
used for selecting patients for intensified treatment. The low sensitivity however 
means that many patients with advanced disease would be missed out if this was the 
only criteria for intensified treatment. 
Local invasion: The presence of local invasion on CT was found to be a significant 
predictor of both NOCD and survival in the present cohort in multivariate analysis. In 
the diagnostic model presented by Favaretto et al., local invasion at CT was found to 
predict NOCD and was included in their diagnostic model. A recently published 
study reported a sensitivity and specificity of 75% and 83% correspondingly using 
CT to detect advanced stage (T3/T4) UTUC [36]. 
Local invasion on CT in the present study showed a relatively low sensitivity of 48% 
but a corresponding high specificity of 85% in predicting NOCD.  By using the 
accuracy from the present study, local invasion at CT as a guide for who could 
benefit from intensified treatment would result in only half of the patients with 
NOCD receiving Neoadjuvant chemotherapy. However, few patients with non-
muscle invasive disease would be “over-treated” with chemotherapy. Patients not 
treated with neoadjuvant chemotherapy, but with MID at final pathology, could be 
treated with adjuvant chemotherapy using the protocol described in the POUT study 
[156]. Pending evidence from high quality randomized studies comparing 
Neoadjuvant with adjuvant chemotherapy in the treatment of UTUC, we suggest that 
this very simple and readily available feature can be used as a guide for selecting 
patients for intensified treatment. 
5.2.5  Diagnostic models 
The demonstrated limitations of single factors available make the use of diagnostic 
models appealing. Several such models have been published, using different 
variables. During our studies of the literature on the topic, it became clear to us that 
none of these diagnostic models had been subject to external validation. After some 
consideration, we found that our cohort could be used to perform an external 
validation of the Margulis nomogram [54]. Margulis et al. published a nomogram 
using histological tumour grade, gross architecture and location from the final 
pathology report to generate a model with an accuracy of 0.77. This work resulted in 
paper 3 in this thesis.  
A diagnostic model should not be taken into clinical practice before its predictive 
ability is tested on a dataset independent of the one used for development.  External 
validation in this setting denotes the testing of a model’s performance in a different 
but similar cohort and preferably by different authors, as opposed to internal 
validation where the model performance is tested on a sample drawn from the 
development cohort. To summarize our findings, we identified the same predictors 
for NOCD as Margulis et al., the model discriminated adequately between patients at 
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low- and high risk of NOCD, and the calibration was adequate, in spite of some 
miscalibration at the low risk levels. We concluded that the nomogram was validated 
for clinical use. 
The big drawback with the Margulis nomogram however, is that the variables used 
were gathered from final pathology after RNU. The assumption is that all these 
variables are available in the preoperative setting and that the nomogram therefore 
can be used preoperatively. It is not yet clear if these assumptions are correct. The 
upgrading from URS biopsy to final pathology has been clearly demonstrated [47]. It 
is probable that the accuracy of the model would be affected if URS biopsies were 
used for the predictions. The ability of URS or radiology to predict tumour 
architecture on the final surgical specimen has been postulated in several papers, but 
has to our knowledge not yet been examined in studies. In our opinion, it is therefore 
necessary to use information regarding assessment of tumour grade and architecture 
determined solely with URS or radiology with caution, when considering the ability 
to predict NOCD. Ideally, a new external validation of the nomogram using true 
preoperative data in a prospective setting should be performed.  
As described, several diagnostic models have been published. However, for the 
proper use of these models, all variables included would have to be available, 
meaning that e.g. a diagnostic URS has to be performed for the purpose of the model. 
Even if all variables are present, the use of the models in clinical practice is unclear. 
In general, the models are precise if all or none of the risk factors are present, while 
in clinical practice, often one or maybe two of these risk factors are present, and the 
precision in prediction is much lower. Though models increase our general 
knowledge about UTUC and can be beneficial in select cases, its use in everyday 
practice is challenging.  
5.2.6    Implications of our findings and conclusions 
In paper 2, we have performed an evaluation of current standard diagnostic work-up 
with special emphasis on detecting potential candidate variables for selecting patients 
for intensified treatment. A novel feature in the preoperative staging, fatty tissue 
reaction surrounding the tumours at CTU has been described, and should be 
examined further. Using the findings from our own research and in the literature we 
conclude that the accuracy of current preoperative staging of UTUC remains 
suboptimal. In the lack of more accurate predictors, it seems local invasion on CTU 
are the most promising feature to use when selecting patients for intensified 
treatment. A proposed flowchart for the diagnostic work-up and treatment of UTUC 




Figure 7. Illustrates a proposed flowchart that can be used in the diagnostic work-up 
and treatment of UTUC.  CTU: CT urography, UUT: Upper urinary tract, NSS: 
Nephron sparing surgery, URS: Ureteroscopy, RNU: Radical nephroureterectomy, 
LND: Lymph node dissection, NOCD: Non-organ confined disease (pT3+ and/or 
N+), OCD: Organ confined disease (pTa-T2N0M0), MID: Muscle invasive disease 
(pT2+), GFR: Glomerular filtration rate 
There is a clear role of the diagnostic URS in case of diagnostic uncertainty or if 
nephron sparing treatment is considered. As a staging procedure however, the URS 
has clear limitations and possible negative side effects, and should be performed only 
in selected cases. The use of diagnostic models can aid in decision making, 
depending on the preoperative data available for the clinician, and can be beneficiary 
in cases of doubt. In paper 3, one of the diagnostic models previously published has 
been validated by our research group, though we acknowledge the need for further 
validation in a truly preoperative setting.   
5.3 On the nephron sparing treatment of UTUC 
There is increasing evidence that preserving kidney function can reduce the risk of 
cardiovascular disease and even improve overall survival [108, 110]. Nephron 
sparing treatment of UTUC can be achieved by a segmental ureter resection or by 
endoscopic tumour ablation through URS or percutaneous access.  
5.3.1  Segmental ureter resection and percutaneous access 
Equivalent oncologic results between SU and RNU have been demonstrated for low-
risk tumours [113]. Regarding high-risk tumours there is less documentation. Existing 
literature indicates that SU can also be an option in selected cases of high-risk UTUC. 
Since the evaluation of SU or tumour ablations using percutaneous access were not a 
topic in any of the published papers included in this thesis, no further discussion on 
these topics will be done here.  
5.3.2 Endoscopic treatment   
This treatment modality has the advantage over SU that it can potentially be used in 
the entire UUT. Endoscopic treatment of UTUC can be done using electrocautery 
fulguration or as laser ablation. Tumour biopsy using a basket has been found to be 
superior to biopsy with forceps. In situ cytology has a sensitivity of up to 90%, and 
could further allow for correct grading of the tumour.  
5.3.3 Review of literature in field  
The first publications in this topic were published in the late 1990s, and included 
patients treated since the mid-1980s [117, 180]. As with other NSS approaches, this 
treatment modality was historically reserved for imperative cases where RNU was 
considered contraindicated due to kidney failure, comorbidities and/or high age. 
However, as results started to show equivalent oncological results compared to RNU 
among patients with favourable tumour characteristics [181], the treatment modality 
gained popularity also in elective cases. Data from the NCR do not include the use of 
endoscopic treatment. Still, a decline in proportion of patients treated by conventional 
surgery was discovered indicating that endoscopic might be increasingly used in 
Norway the last 20 years.  
The largest published series have presented a 5-year CSS of 87-93% [44, 118, 120, 
121], comparable to the outcomes registered in large cohorts of patients treated with 
RNU [63, 90]. Studies comparing directly the outcomes of endoscopic treatment vs 
RNU for low-grade tumours have come to the same conclusion [182, 183]. The 
kidney preservation rates in larger published series have been 67-83%, and recurrence 
rates 55-77% [118, 121].   
5.3.4 Tumour grade 
 The presented results after endoscopic treatment have been shown to be highly 
dependent on histological tumour grade. Grasso et al. have presented a prospective 
study with results regarding 160 UTUC patients treated with either endoscopic 
treatment or RNU followed over a 15-year period with a mean FU of 38.2 months 
[120]. Survival outcomes were favourable for low-grade tumours. High-grade 
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tumours were in that study treated with endoscopic treatment for palliative purposes, 
and demonstrated poor survival with a 2-year OS of only 54%. Tumour grade was at 
multivariate regression analysis the only significant predictor for survival. Larger 
patient series from Cuttress et al. and Scotland et al. have also described considerably 
poorer results for high-grade tumours compared to low-grade tumours [118, 121]. 
Different outcomes according to tumour grade seems well documented. Tumour 
grade is however reported differently in different studies. In the study from Cuttress 
et al. and Scotland et al., the grading is reported according to the old three-tiered 
WHO classification, while Grasso et al. have reported according to the two-tiered 
grading system from 2004. Results of outcomes stratified by grade according to the 
WHO/ISUP classification from 2004 are limited.  
Given the demonstrated difference in outcomes according to tumour grade, it is 
important to be aware of the previously mentioned sampling error at biopsy, as there 
is a considerable risk that a low-grade biopsy would be upgraded to a high-grade 
tumour at final histopathology if a RNU is done. The reason for this upgrading is not 
completely understood, but is probably due to heterogeneity of the tumour and small 
samples at biopsy making accurate assessment of tumour grade more difficult. 
Discordance between tumour grade at URS biopsy and final histopathological 
evaluation after RNU is described in several papers. In the cohort used for paper 2 
and 3 in this thesis, the upgrading from biopsy to RNU specimen was 35%. In a 
recent meta-analysis evaluating 2232 patients in 23 studies, the rate of upgrading in 
different studies varied from 0-97%, the average pooled rate was 34% (CI 23-45%) 
[47]. Downgrading from high grade biopsy to low-grade final specimen after RNU 
was very rare, described in 3% of the biopsies. 
5.3.5 Tumour size 
A population based study analysing OS in patients treated with endoscopic treatment 
or RNU concluded with equivalent results regarding tumours of less <10mm. If the 
tumour was >20mm, the OS was higher in patients treated with RNU. The smallest 
tumour size with equivalent outcomes was for tumours 15mm or smaller [184]. 
Scotland et al. treated tumours with an average size 16.8 mm. Tumour size (>10mm) 
was found to be a predictor of recurrence, but not survival.  
5.3.6 Our results in context  
In paper 4, we describe the results of primary endoscopic treatment of UTUC at our 
hospital during 2001-2012. 43 patients were included in the study. In 15 of these, 
RNU was considered contraindicated, while 28 had an elective indication. The results 
were analysed separately for these two groups. Further analyses were performed 
according to tumour grade. The results were acceptable and comparable to what has 
been reported previously for patients with an elective indication and/or with a low-
grade tumour. The results for patients with high-grade tumours were poor.  
Though the number of patients in the study is low, the study still has some strengths. 
It was prioritized to have a biopsy of the patients, and a histopathological verification 
was present among 40 of the 43 patients (93%). All biopsies were re-examined and 
graded according to the two-tiered WHO/ISUP grading system from 2004. A 
significant proportion (13/40, 35%) of the tumours were high-grade.  
There are a limited number of patients in this study, and all results must be 
interpreted with caution. We still think that some conclusions can be made. Patients 
with low-grade tumour had markedly better DSS and OS compared to patients with 
high-grade tumours (96% vs 39% and 75% vs 23% respectively, both p<0.01). 
Tumour grade was the only significant predictor of DSS in multivariate analysis 
(p=0.003). The outcomes for patients with low-grade tumours are in line with 
previous publications and confirm that histologically verified low-grade tumours are 
suitable for endoscopic treatment. It further confirms that the WHO/ISUP 
classification from 2004 distinguishes between low- and high-grade tumours in the 
UUT in an adequate way that makes it suitable for selecting patients for endoscopic 
treatment. The literature regarding the endoscopic treatment of high-grade tumours is 
limited, and our results help underline that these tumours are not suited for 
endoscopic treatment.  
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A lower KPR (51%) was found in our study compared to what has been presented by 
others. For low-grade tumours the KPR was 60%.  It is important to notice that 4 of 
14 patients treated with RNU had pT0 at final histopathology. In all of these cases, 
URS as a part of FU revealed changes to the urothelium that was misinterpreted as 
urothelial cancer. It seems probable that endoscopic treatment causes changes to the 
urothelium that resembles UTUC, and a biopsy is recommended in cases of doubt. If 
these unnecessary RNUs had been avoided, the KPR among patients with low-grade 
disease would have been comparable to the findings of other authors. Status at first 
FU visit proved to be an excellent predictor of long-term results regarding KPR and 
recurrence. Patients deemed tumour free at first FU had a KPR of 90%. As far as we 
know, this feature has not been described before. The finding is promising, but the 
absolute number of patients is small, and the finding should be confirmed by others 
before firm conclusions are drawn. The recurrence free survival at 76% presented in 
this study was higher than what has been presented by others. We think this is due to 
the way recurrence was defined in our study. A recurrence was only recorded among 
patients tumour free at some point during FU. We would like to argue that this way to 
analyse recurrence is better, since the presence of tumour at first FU often is the result 
of a residual tumour, rather than of a true recurrence.   
5.3.7 Impact and conclusions  
The study confirms that low-grade tumours are suited for endoscopic treatment, and 
should be considered standard treatment if the tumour has a location and size that 
makes it suitable for this treatment modality. Survival results comparable to RNU and 
a kidney preservation rate of 70-80% can be expected. The study further confirms 
that high-grade tumours are not suited for endoscopic treatment, a patient group less 
described in previous literature. Due to the different outcomes according to tumour 
grade, it is important to obtain histological verification of tumour grade through 
biopsy and cytology. The histological tumour grade should be given according to the 
WHO/ISUP grading system from 2004. It is important to be aware of the risk of 
biopsy sampling error, as approximately 1/3 of tumours classified as low-grade at 
biopsy will be upgraded to high-grade if a RNU is performed. A low-grade biopsy 
should be verified as far as possible with cytology and visual assessment of the 
tumour in the same session as the biopsy was taken. In case of recurrence, repeat 
biopsies should be performed to detect a previous misclassification or tumour grade 
progression. Status at first FU is a promising new predictor of recurrence and KPR 
that should be examined further. Current evidence suggests that tumours larger than 
15mm might have poorer outcomes than smaller tumours, and indication in these 
cases should be considered closely. Ipsilateral recurrence after endoscopic treatment 
is frequent, and a stringent FU using both URS and radiology is necessary. The 
optimal FU is not yet clarified.  
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6. Strengths and limitations 
Paper 1 
Paper 1 is based on national data from Norway covering a 20-year period, analysing 
3096 UTUC cases, a sufficient number of cases to make reliable conclusions about a 
relatively rare disease. The NCR has documented a high degree of data quality 
including key aspects such as completeness, comparability and validity [185]. The 
data material was quality assured including a thorough inclusion/exclusion process to 
ensure that the final database was as accurate as possible.  
The study is not without limitations. One weakness of the study is that the analyses 
were based on registry data partly based on clinical reports made from a wide range 
of clinicians, with an inherent risk of coding errors. More specifically the dataset is 
limited by a lack of accurate data regarding tumour stage and specific data on 
treatment e.g. the use of endoscopic treatment. The dataset also has limitations 
regarding the registration of CIS, prior bladder cancer, race and the use of adjuvant 
treatments. These limitations reduce the ability to draw firm conclusions about the 
causality of our findings.  
Paper 2 and 3 
The cohorts used for paper 2 and 3 were gathered from two larger centres in Norway 
to allow sufficient patients to make robust analyses of staging and survival. All CT 
scans were re-evaluated by a uro-radiologist and all re-evaluations of 
histopathological specimens were performed by uro-pathologists (OJH and BC) to 
increase data quality as much as possible. For paper 3, a statistician (JA) aided in 
statistical analyses to ensure that the external validation was performed correctly. 
These studies are done by retrospective analysis of the dataset, with the inherent 
weaknesses associated with this study design. Increasing the number of patients by 
collaborating with additional centres would have increased the generalizability of our 
findings further.  
Paper 4 
This study is strengthened by the review of all histopathological specimens by a 
dedicated uropathologist (OJH). The specimens included 93% of the patients 
available for evaluation using both three- and two-tiered grading systems, which 
enabled robust analyses on outcome stratified by grade. 
This study is a retrospective study, with its associated weaknesses. The study focused 
mostly on histological tumour grade as a predictor of outcome. It is probable that 
other factors contribute as well, such as tumour size, location and multiplicity, though 
the potential impact of these factors were not considered. The validity of the findings 
would have been strengthened if these factors had been considered simultaneously.  
The study concerns a less frequently used treatment for a quite rare disease, which 
explains the patient number in the study. The number of patients and follow-up time 
in this paper are fair compared to other publications. There is however no doubt that 










7. Conclusions   
• The incidence of UTUC in Norway is increasing, and is currently at higher 
level than has been described before outside endemic areas  
• This increase affects all ages above 60 years irrespective of gender and tumour 
location. Survival is improving 
• The reason for this increase is not completely understood, but one possible 
reason could be that older people are more thoroughly examined for symptoms 
compared to earlier 
• Several factors at the CTU were shown to be predictors of pathological tumour 
stage (pT) and prognosis.  Of these, local invasion at CTU is the most 
promising feature to use when selecting patients for intensified treatment 
• The value of the diagnostic URS as a staging procedure for patients set for 
RNU is limited and can probably be omitted in most cases  
• The Margulis nomogram in the preoperative prediction of NOCD is validated 
for clinical use 
• The nomogram should still be used with caution since the variables used when 
generating the nomogram were gathered from final pathology after RNU, and 
is not automatically transferable to a truly preoperative setting 
• Tumour grade assessed using the two-tiered WHO/ISUP (2004) classification 
is confirmed as a suitable predictor for treatment results after endoscopic 
treatment for UTUC  
• Endoscopic treatment for high-grade tumours have poor results, and should be 
used only in very selected cases 
8. Future aspects 
In paper 1, we described an incidence of UTUC in Norway which was higher than 
expected and rapidly increasing. It is so far unclear if this increase is equally present 
in the rest of Europe or even globally, and further studies on the subject from other 
countries are needed. Using our population based cohort, we also had limited 
possibility to assess the causality of the described increase, and further studies are 
needed to explore these questions further. 
Regarding the treatment of UTUC, we have seen an increased focus on individualized 
treatment in the last decade, where both nephron sparing treatments and intensified 
treatment have become increasingly common. Essential in this process is adequate 
clinical staging as examined and discussed in paper 2 and 3. Despite developments in 
staging, further studies are needed. One promising possibility is the use of the MRI 
where the ADC can serve as a potential biomarker for aggressive disease. Another 
interesting topic is the use of confocal laser tumour grade assessment during URS, as 
described in the introduction part of this thesis. The efficacy of perioperative 
chemotherapy has been demonstrated, but it is still unclear if chemotherapy is best 
administered as neoadjuvant or adjuvant treatment. Results from the ongoing 
URANUS trial (Clinical trials no NCT02969083) can hopefully elucidate this 
question. Further high quality studies regarding the use of LND at RNU are also 
highly warranted. Questions remain regarding the potential benefits of the treatment, 
the optimal template for dissection and optimal patient selection. Regarding nephron 
sparing treatment, the use of intra-cavitary gel mitomycin for the treatment of 
tumours of limited size in the renal pelvis is exciting. Studies evaluating follow-up 





In paper 3, supplementary table 1 should be titled as supplementary table 1 in the 
table heading, not as table 3.  
In chapter 4. Summary of results p.46 section 3:  
We found a 5, 10 and 15-year OS of 47.7%, 32.7% and 22% respectively. The 5, 10 
and 15-year CSS was 75.3%, 72.9% and 70.8% respectively. OS improved over time, 
comparing the last decade with the first (five-year OS 44.3% vs 51.7%, p=0.003). No 
differences were found in survival regarding gender or tumour location.  
It should be the same numbers as in the original paper:  
We found a 5, 10 and 15-year OS of 48.3%, 33.2% and 22.5% respectively. The 5, 10 
and 15-year CSS was 61.4%, 56.1% and 51.1% respectively. OS improved over time, 
comparing the last decade with the first (five-year OS 44.0% vs 53.2%, p=<0.001). 
No differences were found in survival regarding gender or tumour location. 
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Abstract
Purpose To register all cases of urothelial cancer and renal cell carcinoma (RCC) in Norway during 1999–2018 to obtain 
the contemporary incidence of UTUC and UTUC incidence relative to other urothelial cancers and RCC. Further to analyse 
possible changes over time regarding UTUC incidence, UTUC patient characteristics, tumour characteristics and survival.
Methods 3502 cases registered with ICD code C65 and C66 during 1999–2018 at the Norwegian cancer registry were 
entered into a database. After a selection process 3096 cases were included in the study. The crude incidences of UTUC were 
calculated for each year adjusting for the corresponding population data. Age-standardized rates adjusting to the European 
standard population (2013) were calculated. Comparisons were made with other cases of urothelial cancer and RCC. For 
changes over time, the material was split into 5-year periods. Regression analysis was used to calculate yearly changes and 
for assessing statistical significance. Survival outcomes were calculated using the Kaplan–Meier method.
Results The overall age-standardized incidence rate was 3.88, increasing from 3.21 to 4.70 from first to last 5-year periods. 
The increase affected all ages except those < 60 years of age, and were observed regardless of gender or anatomical location. 
UTUC constituted 11.8% of all urothelial cancers, increasing from 9.9 to 12.8%. Mean patient age at diagnosis increased 
from 71.5 to 73.4 years. The 5-years Cancer-specific survival improved from 57.4 to 65.4%.
Conclusion The incidence of UTUC was higher than expected and increasing. Patient age at diagnosis was increasing.
Keywords Upper tract urothelial carcinoma · Epidemiology · Incidence · Registry data · Population based study
Introduction
Compared to urothelial cancer of the bladder (BC), upper 
tract urothelial carcinoma (UTUC) is relatively uncom-
mon. The incidence is typically referred to be 1–2:100.000 
per year or 5–10% of all urothelial carcinomas. Urothelial 
cancer in the kidney pelvis has been referred to constitute 
7% of all renal tumours. As a source of these numbers, the 
yearly publication from the American Cancer Society is 
often quoted [1]. In the yearly publication from the Nor-
wegian national database at the Cancer Registry of Norway 
(NCR) all new cancer cases of UTUC are merged with cases 
of the much more common BC and cancer of the urethra 
[2]. Specific contemporary data regarding the incidence of 
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UTUC and changes over time is limited. Some authors have 
reported an increasing incidence of UTUC [3, 4], while oth-
ers have reported a stable incidence, or even a decline [5, 
6]. To our knowledge, currently published papers on this 
topic do not include patient cohorts after 2011. Basic epide-
miological knowledge is essential in the planning of diag-
nostic evaluations, treatment and research of a particular 
disease. We, therefore, decided to gather and analyse avail-
able data regarding UTUC from the NCR in Norway during 
1999–2018. We formulated the following aims for the study.
Primary objective
To register all cases of UTUC together with all other cases 
of urothelial cancer and renal cell carcinoma (RCC) in Nor-
way during 1999–2018 to obtain the contemporary incidence 
of UTUC in Norway together with UTUC incidence relative 
to other urothelial cancers and RCC.
Secondary objective
To look for and analyse possible changes over time regard-
ing UTUC incidence, patient and tumour characteristics and 
survival outcomes.
Material and method
All patients classified with the International Classification 
of Diseases tenth revision [7] (ICD-10) diagnosis code 
C65 (cancer in the kidney pelvis) and C66 (cancer in the 
ureter) registered during 1999–2018 were extracted from 
the main database at NCR. A dataset of 3502 cases was 
obtained. For comparison, a similar extraction was made 
for renal cell carcinoma (RCC, C64, n = 14,500), BC (C67, 
n = 27,427 and Urethral cancer (C68, n = 440). The data-
base included information about patient sex, age at diag-
nosis, date of birth, histopathological data, clinical data 
(cancer report, death report including the cause of death 
etc.), treatment and current status (deceased or alive). The 
data from the NCR include nodal status and metastasis at 
diagnosis if present, but complete data on pathological 
or clinical tumour stage is not available. As a substitute, 
the tumours are coded as invasive (pT2 +) or non-invasive 
(pTa/T1). This classification is available for pure urothe-
lial carcinomas only (see Table 1). The inclusion/exclu-
sion process is illustrated in supplementary Fig. 1. In the 
case of diagnostic uncertainty, the cases were examined 
manually together with NCR personnel to clarify the basis 
of the diagnosis code and consider if the cases could be 
included or not. Of 1026 uncertain UTUC cases, 305 were 
excluded, typically where the diagnosis code was based 
on atypical cells by cytology or biopsy, when the tumour 
was coded wrong and was benign (i.e. benign papilloma) 
or when there was doubt whether the cells were benign 
or malignant. In 29 cases, the diagnosis code was based 
on very sparse information, i.e. only a death report or a 
clinical report based on autopsy or clinical examination, 
and these were excluded. In addition, 72 cases of pure 
non-urothelial cancers (i.e. squamous cell carcinoma or 
adenocarcinoma) were excluded. All cases of pure urothe-
lial carcinoma and cases of urothelial carcinoma with 
divergent differentiation were included. A comprehensive 
list of included and excluded cases is shown in Table 1. 
In all, 3096 cases in 2818 patients were included in the 
final analysis. More than one case of UTUC on the same 
patient was uncommon and only registered if data sug-
gested a truly new tumour, i.e. considerable time between 
cases or a new tumour on the opposite side. All analyses 
were performed according to number of cases, not num-
ber of patients. Of all 3096 cases, 2969 (95.9%) were 
verified with histopathological examination of a surgical 
specimen (n = 2327, 75.2%), biopsy (n = 576, 18.6%) or 
cytology (n = 66, 2.1%). In the remaining 127 (4.1%), the 
basis was a clinical report using radiological examination, 
endoscopic procedure or radiation therapy data as sources 
for the diagnosis codes. Similar inclusion and exclusion 
Table 1  Description of included and excluded cases in the study
a Percentages given as % of both included and excluded cases and 
might differ from % in manuscript
Tumour characteristics n %a
All cases 3502 100
Included 3096 88.4
 Pure urothelial carcinoma 2856 81.6
 Urothelial carcinoma with divergent dif-
ferentiation
45 1.3
 Carcinoma in situ 68 1.9
 No histopathological verification 127 3.6
Excluded 406 11.6
 Other malignant tumour 72 2.1




  Neuroendocrine tumour 4 0.1
  Other 1  < 0.1
 Benign tumour/uncertain 305 8.8
  Urothelial Atypia/dysplasia etc 288 8.2
  Benign tumour 17 0.5
 Limited data available 29 0.8
  Death certificate only 11 0.3
  Autopsy only 8 0.2
  Clinical examination only 10 0.3
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processes were performed regarding BC, urethral cancer 
and RCC resulting in 24,467 included cases of BC, 13,619 
with RCC and 287 with urethral cancer.
For incidence rates, crude rates were calculated using 
population data in Norway corresponding to each year 
from 1999 to 2018. To adjust for demographic differences 
between the Norwegian and other populations, age-standard-
ized rates (ASR) according to the European standard popula-
tion published in 2013 were calculated [8]. ASRs adjusted to 
other available standard populations were also calculated for 
comparison (see supplementary Table 1 and 2).
Statistical analysis
For the purpose of analysing changes over time, the mate-
rial was split into 5-year periods (1999–2003, 2004–2008, 
2009–2013 and 2014–2018). The relative proportion of 
UTUC cases compared to all urothelial cancer cases and 
pelvic urothelial tumour cases compared to RCC cases 
were calculated for each 5-year periods. Analyses regarding 
potential changes in patient age, gender distribution, location 
of the tumour and tumour features were performed in the 
same manner. For further analyses of changes over time, the 
estimated average percentage changes (EAPC) for incidence 
rates were calculated and linear regression analyses were 
used to calculate yearly changes and for assessing statis-
tical significance. Survival analyses included both overall 
survival (OS) and cancer-specific survival (CSS) and were 
performed using the Kaplan–Meier method. Categorical data 
were analysed using the Chi-square method. Data were ana-
lysed using IBM® SPSS® Statistics v. 26. P values less than 
0.05 were considered statistically significant.
Results
The developments in crude rates and ASRs of UTUC dur-
ing the study period are illustrated in Fig. 1. Specific ASR 
regarding UTUC in the kidney pelvis and the ureter are also 
included in the figure. The crude incidence of UTUC in the 
whole time period was 3.17:100.000, increasing from 2.54 
to 3.98 from the first to last 5 year periods. The estimated 
annual increase was 0.09 (CI 0.07–0.12), p < 0.001) result-
ing in an EAPC of 3%. The ASR adjusted to the European 
standard population was 3.88 for the whole period, increas-
ing from 3.21 to 4.70. The increase per year was 0.10 (CI 
0.06–0.13, p < 0.001) with an EAPC of 2.5%. The ASR 
of UTUC in the kidney pelvis increased from 1.77 to 2.88 
from first period to last, p < 0.001. For ureteral tumours 
the increase was from 1.44 to 1.82 during the same period, 
p < 0.001. The proportion of tumours in the renal pelvis 
compared to all UTUC increased non-significantly from 
55.6 to 61.2%, p = 0.06. The ASRs adjusted to other standard 
populations are presented in Supplementary Table 1 and 2.
Analyses showed that UTUC incidence increased in all 
age-spans above 60 years age, see supplementary Fig. 2. 
There was no increase over time in new yearly UTUC cases 
among patients under the age of 60, but comparing first 
5-year periods with the last the increase was apparent and 
significant for each decade from 60 to 69 years (131–254 
cases, 94% increase) 70–79 years (243–399 cases, 64% 
increase) and 80 + years (121–303 cases, 150% increase), 
all p < 0.001.
Patient demographics, tumour features and developments 
over time are shown in Table 2. The table also includes com-
parisons between UTUC and other urothelial cancers and 
RCC.
Mean (median, IQR) age of all UTUC patients during the 
whole period was 72.8 (73.8, 65.8–79.8) years. Patient mean 
age at diagnosis increased from 71.8 to 73.9 from the first 
to last 5 year periods, p < 0.001. No gender-specific changes 
over time were observed.
No statistically significant stage migration over time was 
observed. The proportion of invasive tumours decreased 
non-significantly from 50.0 to 41.7% compared to non-
invasive tumours (p = 0.07). Invasive tumours were equally 
frequent irrespective of gender or age. Similarly, analyses 
were performed regarding regional node or distant metas-
tases, but no differences over time were observed for the 
entire cohort or stratified by age or gender. The proportion 
of cases where invasiveness was not assessable increased 
over time, corresponding to an increase in cases verified by 
biopsy only, and a decrease in radical surgery.
Fig. 1  Demonstrates the 5-years average UTUC incidence per 
100.000 and changes over time. Illustrates the crude rates (blue) and 
the age-standardized incidence rates adjusted to the European stand-
ard population, 2013 version, green). Includes the incidence rates of 
UTUC in the kidney pelvis (red) and the ureter (orange)
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During the whole study period, 75.2% of the patients 
were treated with radical surgery. The absolute number of 
patients treated with radical surgery increased by 55.5% dur-
ing the study period, but since number of cases increased by 
81.4%, there was a net decline in the proportion of patients 
treated with radical surgery over time from 82.6 to 70.8% 
(p < 0.001). The proportion of patients with a biopsy verified 
diagnosis without following radical surgery increased cor-
respondingly from 10.8 to 23.7% in the same period.
Regarding the oldest patients (> 80 years of age) fewer 
patients (59.3%) were treated with radical surgery, decreas-
ing from 64.5 to 55.6% in the study period. More of these 
patients were diagnosed with biopsy without following radi-
cal treatment, increasing from 18.2 to 31.2% in the study 
period. Among these oldest patients, it was also more com-
mon that the diagnosis was not verified with a histopatho-
logical specimen, (16.0% vs 2.8% for patients < 80 years 
age), stable during the study period.
The 5, 10 and 15-years OS were 48.3%, 33.2% and 22.5%, 
respectively. The 5, 10 and 15-years CSS were 61.4%, 56.1% 
and 51.1%, respectively (Fig. 2). All the following survival 
data are given as 5-years CSS. Patients treated with radi-
cal surgery had significantly higher survival compared to 
patients not treated with radical surgery (67.2% vs 41.6%, 
p < 0.001), respectively. The patients with non-invasive 
Table 2  Changes over time regarding patient demographics, tumour features and new cases of upper tract urothelial carcinoma compared to 
other urothelial cancers and renal cell carcinoma
a Increase in percent from first to last 5-year periods
b p values based on regression analyses assessing yearly changes
c Chi-square comparing invasive with non-invasive
Variable All 1999–2003 2004–2008 2009–2013 2014–2018 %a pb
Mean age (years) 72.8 71.8 72.0 72.6 73.9  < 0.001
Gender %
 Female 37 41.1 32.3 39.3 36.1 0.3
 Male 63 58.9 67.7 60.7 63.9
Location
 Kidney pelvis 58.5 55.6 56.1 59.1 61.2 0.06
 Ureter 41.5 44.4 43.9 40.9 38.8
Tumour stage %
 Invasive (T2–T4) 46.9 50.0 47.7 50.7 41.7 0.07c
 Non-invasive (Ta–T1) 41.4 42.5 42.7 39.1 41.8
 Invasiveness not assessable (Tx) 11.7 7.5 9.5 10.1 16.5  < 0.001
 Regional node metastases 5.2 4.7 5.4 6.6 4.2 0.9
 Distant metastases 9.6 9.9 10.4 9.8 8.8 0.5
Upper tract urothelial carcinoma (n) 3096 574 681 800 1041 81  < 0.001
 Bladder cancer 24,467 5251 5910 6181 7125 36  < 0.001
 Urethral cancer 287 61 74 54 98 61 0.2
 Total Urothelial cancer 27,850 5886 6665 7035 8264 40  < 0.001
 % Upper tract urothelial carcinoma 11.1 9.8 10.2 11.4 12.6 29  < 0.001
Renal tumours (n)
 Urothelial carcinoma kidney pelvis 1811 319 382 473 637 100  < 0.001
 Renal cell carcinoma 13,619 2501 3103 3711 4304 72  < 0.001
 Total 15,430 2820 3485 4184 4941 75  < 0.001
 %Upper tract urothelial carcinoma 11.7 11.3 11.0 11.3 12.9 14 0.04
Fig. 2  Shows the estimated overall- and cancer-specific survival 
curves of the entire cohort using the Kaplan–Meier method. The 5, 
10 and 15-years OS were 48.3%, 33.2% and 22.5%, respectively. The 
5, 10 and 15-years CSS were 61.4%, 56.1% and 51.1%, respectively
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tumours had higher survival compared to patients with 
invasive UTUC (79.4% vs 49.8%, p < 0.001). Survival dete-
riorated with increasing age, patients < 70 years 68.1%, 
70–80 age 63.5% and > 80 years of age 46.7%, respectively, 
p < 0.001. No differences in survival stratified by gender or 
tumour location were detected.
Both OS and CSS improved over time, comparing the last 
decade with the first (5-year OS 44.0% vs 53.2%, p ≤ 0.001 
and 5-year CSS 57.4% vs 65.4%, p ≤ 0.001), respectively. 
This improvement over time was present for all sub-groups 
irrespective of age, gender, type of treatment and tumour 
location.
Discussion
If the commonly quoted incidence rate of 1–2:100.000 
from the American Cancer society serves as a reference, the 
ASR of 4.7:100.000 in the present study was higher than 
expected, and to our knowledge the highest incidence rate 
published based on a population outside endemic areas. 
There was an estimated annual percentage change in the 
incidence rate of 2.5%, corresponding to an 81% increase in 
new cases comparing first with last 5-year periods.
The reason for the demonstrated increase is not clear. One 
possible explanation could be that symptoms i.e. haema-
turia are more vigorously examined in older patients now 
than before. An improved access to high-quality computed 
tomography and better equipment for flexible ureteroscopy 
could add to this effect. This could lead to a higher detection 
rate of UTUC and increased age at diagnosis. Indeed, we 
have seen a considerable increase in biopsy verified cases 
without following radical surgeries. This increase is even 
more evident among patients > 80 years of age, the same age 
group that showed the greatest increase in new yearly cases. 
These data indicate that at least some of the demonstrated 
increase in incidence could be due to increased diagnostics, 
especially among the oldest patients.
The decrease in radical treatments could be caused by an 
increased use of endoscopic treatment. Unfortunately, the 
data from the NCR does not include data on endoscopic 
treatment. However, an increasing number of publications 
with relatively larger cohorts on the use of endoscopic 
treatment could indicate an increased use of this treatment 
modality [9, 10]. Another reason could be that observation 
was chosen over radical surgery due to high age, poor per-
formance status or favourable tumour characteristics. Data 
on performance status are not available in the present data-
set, but a considerable and increasing proportion of patients 
were at a high age where larger surgeries might not be 
recommended.
In spite of these possible reasons for the described 
increase, it seems likely that there is a true increase in 
UTUC in Norway for the last 20 years, and not just an 
increased detection rate. The known risk factors for UTUC 
include smoking [11, 12], excessive alcohol consump-
tion and exposure to aristolochic acid [13]. The dataset 
obtained from the NCR does not contain information about 
smoking, alcohol use or exposure to possible carcinogens. 
An evaluation about the potential effect of changing expo-
sure to known risk factors is for this reason not possible 
without obtaining further data and was beyond the scope 
of this paper. Further studies to clarify the reasons for the 
described increase are needed.
In the present cohort, we found an all-cohort 5-years 
CSS and OS of 61.4% and 48.3%, respectively. Other pop-
ulation-based publications on UTUC which include sur-
vival data have demonstrated similar survival outcomes. 
Raman et  al. presented a 5-years OS of ~ 50% in their 
cohort [3], while Eylert et al. reported a falling 5-years 
relative survival rate from 60 to 48% during their study 
period [14]. Woodford et al. reported a 5-years overall 
survival rate of 32% [5]. Compared to these more historic 
cohorts, the present study demonstrated comparable or 
favourable survival outcomes. A moderate improvement 
in survival over time was observed. The reason for this 
improvement is unclear. Increased use of adjuvant thera-
pies for UTUC including both perioperative chemotherapy 
[15, 16] and the introduction of immunotherapies [17] 
could possibly explain some of the demonstrated improved 
survival in the present cohort. Unfortunately, the data at 
NCR is very limited regarding the use of adjuvant treat-
ment, and no firm conclusions can be drawn.
As UTUC is a potentially lethal disease if left untreated, 
one would expect that earlier detection and treatment 
could result in improved survival. In the present cohort, 
we found an increased use of biopsies without following 
radical treatment. As stated earlier, the present data set is 
not complete regarding tumour stage, but a non-signifi-
cant decline in the proportion of invasive tumours was 
observed. It is possible that more cases are detected at an 
earlier stage presently compared to previously, resulting 
in improved survival.
Our findings could have several possible implications. 
One implication could be an increased focus on UTUC, 
simply because more patients than expected would be 
affected by the disease. Another implication could be 
enrolment into studies. There are many unanswered ques-
tions regarding the diagnostic work-up and treatment of 
UTUC, such as the optimal use of perioperative chemo-
therapy or the use of lymph node dissection at the time of 
RNU. A higher incidence would result in quicker enrol-
ment into much needed studies on the topic, and make 
studies with adequate patient numbers more feasible to 
conduct.
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Strengths and weaknesses
The present publication is based on national data from 
Norway, analysing 3096 UTUC cases during 20 years, a 
sufficient number of cases to make reliable conclusions 
about a relatively rare disease. The NCR is nationwide and 
has since 1953 kept a complete registry of all new cases of 
malignant neoplasms. It has documented a high degree of 
data quality including key aspects such as completeness, 
comparability and validity [18]. The data material was 
quality assured, based on clinical and pathology reports, 
and statistical advice was sought to make sure the methods 
used for incidence measurements, population adjustment 
and changes over time were performed in the correct way.
This study is not without limitations. One weakness of 
the study is that the analyses were based on registry data 
partly based on clinical reports made from a wide range 
of clinicians, with an inherent risk of coding errors. More 
specifically the dataset is limited by a lack of accurate 
data regarding tumour stage and specific data on treatment 
i.e. the use of endoscopic treatment. The data also has 
limitations regarding the registration of CIS, prior blad-
der cancer, race and the use of adjuvant treatments. As the 
present study is a population-based registry study with the 
described limitations, the ability to draw firm conclusions 
about the causality concerning our findings is limited. 
Further studies to explore further possible reasons for the 
increased incidence, changing demographics and improved 
survival are warranted.
Conclusion
The incidence of UTUC was higher than previously 
reported, and increasing. UTUC incidence in Norway during 
2014–2018 was 4.7:100.000. UTUC currently constitutes 
close to 13% of all urothelial cancers, and urothelial cancers 
of the renal pelvis currently constitute close to 13% of all 
malignant renal tumours. The increase was not accompanied 
by stage migration, but survival moderately improved. The 
patients are older at the time of diagnosis currently com-
pared to earlier, but no other changes in patient demograph-
ics were detected.
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Supplementary table 1. Table showing different standard populations that can be used for 
calculation of age standardized incidence rates.  Note the different weights especially at high 
ages. This causes the relatively large differences in age standardized incidence rates 











00-04 0,05 0,08 0,069135 0,120 0,059 
05-09 0,055 0,07 0,072533 0,100 0,066 
10-14 0,055 0,07 0,073032 0,090 0,062 
15-19 0,055 0,07 0,072169 0,090 0,058 
20-24 0,06 0,07 0,066478 0,080 0,061 
25-29 0,06 0,07 0,064529 0,080 0,068 
30-34 0,065 0,07 0,071044 0,060 0,073 
35-39 0,07 0,07 0,080762 0,060 0,073 
40-44 0,07 0,07 0,081851 0,060 0,07 
45-49 0,07 0,07 0,072118 0,060 0,069 
50-54 0,07 0,07 0,062716 0,050 0,074 
55-59 0,065 0,06 0,048454 0,040 0,061 
60-64 0,06 0,05 0,038793 0,040 0,048 
65-69 0,055 0,04 0,034264 0,030 0,041 
70-74 0,05 0,03 0,031773 0,020 0,039 
75-79 0,04 0,02 0,026999 0,010 0,035 
80-84 0,025 0,01 0,017842 0,005 0,024 
85+ 0,025 0,01 0,015508 0,005 0,019 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Preoperative predictors of pathological tumour stage and prognosis may be
used when selecting candidates for intensified treatment in upper tract
urothelial carcinoma
Bjarte Almåsa , Stein Øverbyb, Ole J. Halvorsenc,d, Lars A. R. Reisætere, Birgitte Carlsenf and
Christian Beislanda,c
aDepartment of Urology, Haukeland University Hospital, Bergen, Norway; bDepartment of Urology, Vestfold Hospital Trust, Tønsberg,
Norway; cDepartment of Clinical Medicine, University of Bergen, Bergen, Norway; dDepartment of Clinical Medicine, Section for Pathology,
Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway; eDepartment of Radiology, Haukeland University Hospital,
Bergen, Norway; fDepartment of Pathology, Vestfold Hospital Trust, Tønsberg, Norway
ABSTRACT
Purpose: Intensified treatment such as extended lymph node dissection (LND) and/or perioperative
chemotherapy in addition to radical nephroureterectomy (RNU) has been suggested for high-risk cases
of upper tract urothelial carcinoma (UTUC). We aimed to identify preoperative predictors of tumour
stage and prognosis in the diagnostic work-up before RNU. Further to evaluate if our findings could
be used in selecting patients for intensified treatment.
Patients and methods: A total of 179 patients treated with RNU for UTUC at Haukeland University
Hospital (HUS) and Vestfold Hospital Trust (VHT) during 2005–2017 were included in this retrospective
study. All relevant preoperative variables regarding the patient, the CT and the ureteroscopy (URS)
were registered and analysed regarding their ability to predict non-organ confined disease (NOCD,
pT3þ and/or Nþ) at final pathology after RNU. The prognosis was assessed calculating survival for the
cohort and stratified by preoperative variables.
Results: Local invasion and pathological lymph nodes at CT predicted NOCD in uni and multivariate
regression analyses (OR 3.36, p¼.004 and OR 6.21, p¼.03, respectively). Reactive oedema surrounding
the tumour (OR 2.55, p¼.02), tumour size (4.8 vs. 3.9 cm, p¼.006) and high-grade tumour at URS
biopsy (OR 3.59, p¼.04) predicted NOCD at univariate regression analyses. The 5-year CSS and OS for
the entire cohort was 79% and 60%. ECOG, local invasion, pathological lymph nodes and reactive
oedema surrounding the tumour at CT predicted CSS.
Conclusions: Several variables at the CT predicted both stage and survival. Local invasion at CT seems
the most promising feature for selecting patients for intensified treatment.
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Urothelial carcinoma in the upper urinary tract (UTUC) is
referred to constitute 5–10% of all urothelial carcinomas [1].
UTUC is an aggressive disease and at diagnosis about 40% of
the tumours are non-organ confined. The 5-year cancer-
specific survival (CSS) in these cases is below 50% [2,3]. The
standard treatment of invasive UTUC is a radical nephroureter-
ectomy (RNU) with complete excision of the ipsilateral bladder
cuff. Due to the high mortality of the disease, intensified treat-
ment including chemotherapy as neo-adjuvant or adjuvant
treatment or extended lymph node dissection (LND) have
been suggested for high-risk patients [4–7]. Due to the lack of
accurate staging tools of the disease preoperatively, it can be
challenging to identify the right indication for intensified treat-
ment. Current EAU-guidelines recommend computed tomog-
raphy (CT) urography as standard in diagnosis and
preoperative staging of UTUC. A ureteroscopy (URS) is recom-
mended if imaging and cytology are not sufficient for the
diagnosis and/or risk-stratification of the tumour [8].
The aim of this study was to analyse available preopera-
tive factors regarding their ability to predict histopathological
tumour stage and subsequent prognosis after RNU for UTUC
in a contemporary cohort in Norway. We further sought to
evaluate if our findings could be used in the selection of
patients for intensified treatment.
Material and method
Patient selection
After obtaining approval from the Regional ethics committee
(reference no. 2017/854), the medical records of 209 patients
treated with a RNU between 2005 and 2017 for suspected
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UTUC at Haukeland University Hospital (HUS, n¼ 130) and
the Vestfold Hospital Trust (VHT, n¼ 79), were retrospectively
examined. A total of 30 patients were excluded due to con-
comitant bladder cancer with cystectomy in the same pro-
cedure as RNU (n¼ 9), non-urothelial cancer (n¼ 15, most of
them renal cell carcinoma) or no malignancy detected at the
final histopathological specimen after RNU (n¼ 6), leaving
179 patients for inclusion in the study.
Diagnostic work-up, treatment and follow-up
Standard preoperative assessment was a CT scan with con-
trast unless contraindicated. If there was doubt about the
diagnosis or the patient was a potential candidate for kidney
sparing treatment, a URS was performed. Endoscopic treat-
ment or segmental ureter resection was considered among
patients with low-stage UTUC of limited size clinically. The
indication for RNU was a high-grade or invasive UTUC unless
contraindicated due to comorbidity and/or high age. The
RNU was performed as an open or laparoscopic procedure
with complete excision of the bladder cuff. Chemotherapy
was not standard treatment and neo-adjuvant chemotherapy
was given to only one patient prior to RNU. LND was per-
formed at the discretion of the surgeon. Follow-up included
cystoscopy every three months for the first two years. A CT
scan was commonly performed after 12 months or whenever
the patient presented with symptoms suggestive of meta-
static disease. Later follow-up was individualized.
Patient factors
Patient age, sex, comorbidities, kidney function, presenting
symptoms and smoking status were registered together with
the presence of prior bladder cancer or prior endoscopic
treatment for UTUC.
Radiological analysis
A total of 176 (98%) of the patients were examined with a
CT scan, 159 (90%) of these with a contrast-enhanced CT, 17
patients were examined with a CT without contrast due to
kidney failure. One patient was examined with magnetic res-
onance imaging only, one with a conventional intravenous
urography only and one lacked preoperative radiological
examination of the upper urinary tract. All CT scans were re-
evaluated by a uro-radiologist (LAR) together with a urologist
(BA) and assessed regarding tumour size, location, contrast
enhancement, the presence of hydronephrosis, pathological
lymph nodes, reactive oedema surrounding the tumour and
local invasion into renal parenchyma, the renal pelvis or peri-
ureteric tissue. Each variable was considered by the radiolo-
gist in each patient to assess if a reliable measurement could
be made in that particular case. If for example reliable meas-
urements regarding tumour size and/or contrast enhance-
ment could not be made in one particular case, the variable
was recorded as missing in the dataset. This results in a dif-
ferent number of patients available for analysis for each vari-
able, as demonstrated in Table 3.
Ureteroscopy with biopsy and cytology evaluation
A total of 95 (53%) patients were examined with a preopera-
tive URS with biopsy before RNU. A total of 60 patients were
examined with a preoperative urinary cytology and 43 of
these had cytology taken during URS. The ability of the
biopsy to confirm UTUC diagnosis was registered together
with information about biopsy tumour grade and stage.
Histopathological examination
Data regarding tumour location, stage and grade were gath-
ered from the pathology reports at the respective institu-
tions. Tumours were graded according to the two-tiered
WHO 2004 classification [9] and staged according to TNM
2017 classification [10]. All specimens originally not concur-
ring with these two classifications were re-examined and
reclassified by uropathologists (OJH and BC).
Statistical analysis; prediction of prognosis and
tumour stage
Continuous and categorical variables were analysed using a
Student’s t-test and a chi-square test, respectively. Survival
estimates were calculated using the Kaplan–Meier method,
and a log-rank test was used to compare groups. The esti-
mated 5- and 10 year overall survival (OS) and cancer (UTUC)
specific survival (CSS) were calculated for the entire cohort.
Furthermore, multivariate cox regression analyses including
both patient features and final histopathology were per-
formed to evaluate independent predictors of all-cause and
cancer-specific mortality. The purpose of these analyses was
to evaluate if survival and prognostic factors in the present
cohort were similar to other larger published patient series
on operated UTUC patients.
Univariate prediction of prognosis according to pure pre-
operative variables was then assessed by Kaplan–Meier esti-
mates. Recurrence and metastasis after RNU for UTUC will in
most cases result in death from UTUC, thus 5-year CSS was
chosen as the primary outcome parameter. For prediction of
tumour stage at final histopathological examination after
RNU, all candidate variables regarding patient features, CT
and ureteroscopic findings were analysed using univariate
and multivariate logistic regression analysis to assess their
abilities to predict non-organ confined disease (NOCD).
NOCD was defined as pT3 or more (invasion into the renal
parenchyma, renal pelvis or periureteral tissue) and/or Nþ
(lymph node positive) at final pathology.
Both the cox and logistic multivariate regression analyses
were performed in a backward manner. To pre-select
included candidate variables a cut off of p<.2 in univariate
analyses were chosen. For all analyses, a p value less than
.05 were considered statistically significant. All analyses were
performed by use of SPSS version 26.0 (IBM, Armonk, NY).
Results
The patient demographics and tumour characteristics are
presented in Table 1.
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Prediction of survival
The 5- and 10 year CSS of the whole cohort was 79% and
75%, respectively. The 5- and 10-year OS was 60% and 35%,
respectively. Patients with OCD had a higher CSS (93% vs.
55%, p<.001) and OS (71% vs. 42%, p<.001) compared to
patients with NOCD (Supplementary Figures 1 and 2). Mean
(median) follow-up time in patients alive without recurrence
was 58 (47) months. In a multivariate cox regression analysis,
pathological tumour stage and ECOG were significant predic-
tors of all-cause mortality. Pathological tumour stage
predicted UTUC specific mortality (Supplementary Tables 1
and 2).
The presence of local invasion (64% vs. 86%, p¼ 0.002),
pathological lymph nodes (41% vs. 83%, p<.001) and fatty
tissue reaction surrounding the tumour (58% vs. 84%,
p¼.001) at CT predicted CSS in the present material.
Regarding patient factors, ECOG 0 predicted improved CSS
compared to ECOG  1 (85% vs. 70%, p¼.03). No other fea-
tures regarding the patient, radiological examinations or ure-
terrenoscopic variables predicted CSS in this study.
Prediction of tumour stage
Patient features
The results of the univariate regression analyses regarding
patient factors ability to predict NOCD are shown in Table 2.
No patient factors were shown to be predictors of NOCD at
final pathology in this study.
Radiological variables
The results of the univariate regression analyses regarding CT
variables are shown in Table 3. Non-organ confined tumours
were larger than organ-confined tumours (4.8 cm vs. 3.9 cm,
p¼.006). The presence of reactive oedema in the fatty tissue
surrounding the tumour predicted NOCD (OR 2.55, p¼.016).
This was particularly true for tumours in the ureter with an
OR of 8.0 for those tumours (p¼.002). The presence of patho-
logical lymph nodes and local invasion on CT predicted
NOCD (OR 14.5, p¼.001 and 5.31, p<.001, respectively). The
sensitivity and specificity of local invasion at CT to predict
NOCD was 49% and 85%, respectively. The sensitivity and
specificity of pathological lymph nodes CT to predict NOCD
was 22% and 98%, respectively. Hydronephrosis was present
in 114 of 173 patients (66%). Contrast enhancement and the
presence of hydronephrosis did not predict NOCD in this
patient material.
Ureterrenoscopic variables
The results of the univariate regression analyses regarding
the ureterrenoscopic variables are described in Table 4. A
diagnostic URS with biopsy was performed in 95 patients. In
66 (69%) of the patients, the biopsy could be used to con-
firm UTUC diagnosis, and in 57 (60%) the biopsy material
was sufficient to determine tumour grade. Presence of high-
grade tumour at biopsy predicted NOCD (OR 3.59, p¼.04).
The sensitivity and specificity of high-grade biopsy to predict
NOCD was 63% and 68%, respectively. Out of 34 low-grade
tumours at biopsy, 12 (35%) were upgraded to high-grade at
final pathology after RNU. No high-grade tumours were
downgraded. The tumour stage at biopsy did not predict
NOCD in the present material. A cytology sample was taken
in 60 patients, 43 of these taken during URS. Malignant cells
were detected among 37 (62%) of these. Malignant cells at
cytology did not predict NOCD in the present material.
Table 1. Patient and tumour characteristics.
Percentage
of total












Current smoker 63 35
Previous smoker 48 27

















aEastern Cooperative oncology group.
btumour grade according to WHO/ISUP classification 2004.
cpT3 or more and/or Nþ disease at final pathology after nephroureterectomy.
Table 2. Univariate odds ratios for non-organ confined disease according to
patient risk variable.
Variable ORb 95 % CIa p Value
Age 0.99 0.96–1.02 .5
Female vs. male 1.07 0.56–2.02 .8
Symptoms
Local vs. none 1.26 0.63–2.53 .5
ECOGc
1 or more vs. 0 1.03 0.56–1.89 .9
Smoking status
Never smoking vs. history of smoking 1.68 0.90–3.11 .1
Previous bladder cancer 0.93 0.45–1.90 .8
Previous endoscopic treatment 0.51 0.18–1.47 .2
Tumour location
Ureter vs. kidney pelvis 0.71 0.37–1.34 .3




cEastern cooperative oncology group.
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Multivariate analyses
All variables with a predictive value for NOCD with a p-value
<0.2 (smoking status, presence of hydronephrosis, fatty tis-
sue reactive oedema or pathological lymph nodes together
with tumour size and local invasion at CT) were entered into
a multivariate logistic regression analysis. The results from
these analyses are shown in Table 5. Pathological lymph
nodes and local invasion on CT remained significant predic-
tors of NOCD (6.21, p¼.03 and 3.36, p¼.004, respectively).
Discussion
In this study, several variables from the CT images and
biopsy tumour grade were identified as preoperative predic-
tors for NOCD. With the exception of biopsy tumour grade
and tumour size, these factors also predicted survival.
One of the unanswered questions regarding the preopera-
tive diagnostic procedures before RNU for UTUC is the role
of the diagnostic URS. In the current EAU-guidelines, a URS is
recommended if imaging and cytology are not sufficient for
the diagnosis and/or risk-stratification of the tumour [8].
There is a role for the diagnostic URS in case the result of
the CT is unclear and further examinations to set the correct
diagnosis are necessary. Moreover, another indication is if the
patient is a potential candidate for nephron-sparing treat-
ment, such as a segmental ureter resection or endoscopic
laser tumour ablation. The evaluation of the diagnostic URS
in these settings was not among the aims of this paper, and
will not be discussed further here.
When it comes to the staging of UTUC, the role of the
diagnostic URS is much more unclear. Tumour grade is
regarded as a predictor of tumour stage at final pathology
[2]. However, the problem with tumour grade from biopsy is
that it is often not possible to get a biopsy at all at the pro-
cedure, and in case a low-grade biopsy is found, it is fre-
quently upgraded to high-grade at final pathology. In the
present paper, the biopsy could confirm UTUC diagnosis
only in 69% of the cases. This might seem like a low rate of
histological verification, but is in line with the findings in a
prospective study evaluating URS biopsies. Breda et al. found
that a histological evaluation was possible in 78% of the
biopsies, with complete histopathological assessment only
among 46%. [11]. One could of course turn this around and
say that histological confirmation from URS biopsy is possible
in a majority of the cases, and such verification is a require-
ment for the oncologists before considering neo-adjuvant
chemotherapy. However, histological verification can also be
achieved through cytology at cystoscopy which is mandatory
before RNU. In the present cohort, the sensitivity of cytology
to verify UTUC was 62%, not very different from the sensitiv-
ity of 69% from the URS biopsy. Another aspect of the URS
biopsy was that 35% of the low-grade biopsies were
upgraded to high-grade at final pathology. Such upgrading
is a known phenomenon. A meta-analysis on the topic analy-
sing more than 2000 URS biopsies from 23 studies concluded
that the pooled upgrading rate from low- to high-grade
tumours was at 34% [12], and thus in line with our results.
Table 4. Results of the analyses made from the ureterenoscopic variables
regarding determination of biopsy tumour grade and prediction of non-organ
confined disease at final pathology after nephroureterectomy.
Variable n % ORa CIb p Value
Diagnostic URS performed 95 100
Biopsy method
Forceps only 66 70
Basket only 14 15
Both forceps and basket 13 14
N/A 2 2
Biopsy verified UTUC 66 69
Biopsy WHO grade 2004 57 60
High grade 23 3.59 1.07–12.0 .04
Low grade 34
Low-grade tumours at URS 34
Remain low-grade at final
pathology
22 65c
Upgraded to high-grade at
final pathology
12 35c
Biopsy tumour stage 60 63
Ta/Tx 50
T1 or T2 10 3.55 0.87–14.5 .08
Cytology taken 60 63
Malignant cells 37 1.84 0.55–6.14 .3
aOdds ratios.
bConfidence interval.
cPercentage of low-grade tumours at biopsy either verified as low-grade
tumours or upgraded to high-grade tumours at final pathology after radical
nephroureterectomy.
Table 3. Univariate analyses for prediction of non-organ confined disease according to variables at CT scan.
Variable n (%)a
Continuous variables All NOCD 95% CIb OCD 95% CIc p Value
Tumour size (cm) 163 (91) 4.2 4.8 4.2–5.3 3.9 3.6–4.3 .006d
Contrast enhancement (HU) 111(62) 38 36 32–40 39 35–43 .4a
Categorical variables ORe 95% CIb p
Fatty tissue oedema (all) 164 (92) 2.55 1.19–5.46 .016b
Fatty tissue oedema (ureter only) 55 (31) 8.0 2.13–30.1 .002b
Hydronephrosis 173 (97) 0.62 0.32–1.17 .14b
Pathological lymph nodes 173 (97) 14.5 3.19–66.4 .001b
Local invasion 162 (91) 5.31 2.53–11.1 <.001b
Tumour size, oedema in the fatty tissue surrounding the tumour, the presence of pathological lymph nodes and local invasion into renal,
peripelvic or periureteric tissue were shown to be significant predictors of non-organ confined disease at final pathology after
nephroureterectomy.
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In spite of the demonstrated limitations regarding the
diagnostic URS, biopsy tumour grade was still a significant
predictor of NOCD at univariate analyses in the present
material, and further analyses were made to assess potential
clinical benefit. The sensitivity and specificity of high-grade
tumour at biopsy to predict NOCD were 63% and 68%,
respectively. We think that the accuracies of these predic-
tions are too low to be clinically useful. Furthermore, there is
also the aspect that URS requires time and resources, and
thus delays definite treatment. Finally, in two meta-analyses,
an increased risk of post-RNU bladder recurrence has been
demonstrated among patients examined with URS [13,14].
To conclude, URS as a diagnostic measure among patients
where a decision for RNU has already been made has consid-
erable limitations, and will only rarely influence the decision
about intensified treatment. It causes curative treatment
delay and an increased risk of bladder recurrence after RNU.
We argue that a preoperative URS should be spared for cases
where the diagnosis is uncertain or when nephron-sparing
treatment might be an option.
How can our findings be used in a clinical practice? If a
URS is omitted in the preoperative diagnostic work-up, the
clinician is left with the findings (a) in the CT scan and (b) at
cystoscopy visit when deciding on potential intensified treat-
ment. There is emerging evidence of the efficacy of peri-
operative chemotherapy, but selecting the appropriate
patients for this is challenging. Indeed, in Norway, different
approaches to perioperative chemotherapy at different hos-
pitals exist. The POUT study has recently demonstrated the
efficacy of adjuvant chemotherapy in case of muscle-invasive
disease [4], and one could argue that the best strategy is
simply to wait for final pathology and then decide whether
to give adjuvant chemotherapy or not. However, neo-adju-
vant chemotherapy in the treatment of UTUC has some
appealing advantages. Neo-adjuvant chemotherapy before
cystectomy for bladder cancer has demonstrated survival
benefit, and is standard treatment according to guidelines
[15]. Second and perhaps more importantly, a RNU will inev-
itably reduce the kidney function of the patient. We know
that this will make a significant proportion of the patients
ineligible for adjuvant chemotherapy due to reduced kidney
function postoperatively. On the other hand, giving neo-
adjuvant to all chemo-eligible patients undergoing RNU will
inevitably result in giving a toxic and potentially lethal treat-
ment to a large group of patients with non-muscle invasive
disease. In the present material, the proportion of patients
with Ta and T1 disease was 47%. The proportion of patients
with organ-confined disease was 62%. We think that giving
neo-adjuvant treatment to patients with non-muscle invasive
disease would result in unacceptable side effects to a patient
group where the potential benefit of the treatment is
highly debatable.
So how can we select the appropriate patients for neo-
adjuvant chemotherapy? Both pathological lymph nodes and
fatty tissue oedema predicted NOCD in the present cohort.
However pathological lymph nodes had a very low sensitivity
of 22% in predicting NOCD and would result in missing out
many potential candidates for neo-adjuvant chemotherapy.
Fatty tissue reaction surrounding the tumour also demon-
strated predictive ability, but this is a feature that to our
knowledge has not been demonstrated as a predictor for
tumour stage after RNU before. Its predictive abilities should
be confirmed in further studies before it is taken into stand-
ard clinical practice.
The presence of local invasion on CT seems a more prom-
ising feature to use in patient selection for neo-adjuvant
chemotherapy. It was found to be a significant predictor of
NOCD and survival in the present cohort. The predictive abil-
ity of local invasion at CT has been described by other
authors. In a diagnostic model presented by Favaretto et al.,
local invasion at CT was found to predict NOCD and was
used as a part of their presented diagnostic model [16]. A
recently published study reported a sensitivity and specificity
of 75% and 83% correspondingly using CT to detect
advanced stage (T3/T4) UTUC [17].
Local invasion on CT in this study showed a relatively low
sensitivity of 48% but a corresponding high specificity of
85% in predicting NOCD. A sensitivity of 48% might seem
unacceptably low, but this sensitivity as a cut off is the same
as suggested in a recently published model by Petros et al.
The authors of that study generated a predictive model that
included findings at CT, URS and blood samples to reach a
sensitivity of 49% and specificity of 95% in predicting NOCD
[18]. The higher specificity demonstrated in their model is
beneficiary, but comes at the cost of a highly complicated
model using parameters from URS and blood samples in
addition to findings at the CT in a nomogram. In our opin-
ion, the complexity of the model makes it less useful in day
to day clinical practice.
By using the accuracy from this study, invasion at CT as a
guide for who could benefit from neo-adjuvant, would result
in only half of the patients with NOCD receiving chemo as a
Table 5. Multivariate regression analyses for prediction of NOCD at final specimen according to risk variables.
Variable
ORa CIb p Value
Tumour size at CT 0.94 0.77–1.16 .6
History of smoking vs. never smokers 1.53 0.72–3.24 .3
Hydronephrosis at CT 0.59 0.28–1.23 .2
Reactive oedema in fatty tissue surrounding tumour at CT 0.62 0.26–1.50 .3
Pathological lymph nodes at CT 6.21 1.21–31.3 .03
Local invasion into renal parenchyma or periureteric tissue 3.36 1.47–7.69 .004
Variables with a p value of <.2 were taken into the analysis. Pathological lymph nodes and local invasion into renal par-
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neoadjuvant. However, few patients with non-muscle inva-
sive disease would be ‘overtreated’ with chemotherapy. The
patients with muscle-invasive disease that did not receive
neo-adjuvant chemotherapy could be good candidates for
adjuvant chemotherapy. If the kidney function was still
acceptable (GFR > 55), Cisplatin-based regimens would be
preferred. If not, Carboplatin based regimens could be an
option. Both these regimens of adjuvant chemotherapy were
included and shown to be beneficial in the POUT study.
High-quality randomized studies comparing neo-adjuvant
Figure 1. Demonstrating a proposed flowchart that can be used in the selection of patients for perioperative chemotherapy and/or extended LND in adjunct to
radical nephroureterectomy for upper tract urothelial carcinoma. UTUC: upper tract urothelial carcinoma. RNU: Radical nephroureterectomy. LND: Lymph node dis-
section; NOCD: non-organ confined disease; OCD: organ-confined disease; MID: muscle-invasive disease; GFR: glomerular filtration rate.
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with adjuvant chemotherapy in the treatment of UTUC are
urgently needed. Pending evidence from such high-quality
studies, we suggest that this very simple and readily avail-
able feature can be used as a guide for selecting patients for
either neo-adjuvant or adjuvant chemotherapy. Its use is
demonstrated in a proposed flowchart (Figure 1).
The same approach can be used when selecting patients
for extended LND. Current EAU guidelines recommend that a
template-based LND should be performed during RNU [8]. In
case pathological but resectable lymph nodes are present on
the preoperative CT, an LND should be performed. However,
the presence of lymph nodes metastasis is strongly depend-
ent on tumour stage, and an LND appears to be unnecessary
in Ta/T1 tumours [19]. In case the CT is negative for patho-
logical lymph nodes but local invasion is present, an LND
could be performed with an indication similar to that of neo-
adjuvant chemotherapy (Figure 1).
The inclusion of survival analyses presented in this study
serve two purposes. First, the 5-year DSS of 79% in this study
is comparable to the DSS presented in larger cohorts [20,21].
This suggests that our cohort is a representative sample of
UTUC cohorts in general, and could increase the generaliz-
ability of our findings. Second, the same predictors of
tumour stage at CT also predicted survival in our study. This
was as expected, but these findings further underscore the
importance of the predictors we discovered both regarding
stage and survival.
Strengths and weaknesses
The strengths of this article include using patients from two
larger centres in Norway to allow enough patients to make
robust analyses of staging and survival. However, increasing
the number of patients by collaborating with additional
centres would have increased the generalizability of our find-
ings further. All CT scans were re-evaluated by a uro-radiolo-
gist and all re-evaluations of histopathological specimens
were performed by uro-pathologists to increase data quality
as much as possible. The weakness of the study is its retro-
spective study design, with the inherent weaknesses associ-
ated with this study design.
Conclusion
Several features in the preoperative diagnostics before RNU
for UTUC were shown to predict tumour stage and survival
in this study. Of these, local invasion on CT seems to be the
most promising feature when selecting the appropriate
patients for intensified treatment for UTUC. The role of the
diagnostic URS in the staging of UTUC seems limited. The
preoperative staging of UTUC before RNU remains challeng-
ing, and further studies on the topic are warranted.
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Supplementary table 1. Multivariate regression analyses for prediction of all-cause mortality 
after radical nephroureterectomy for upper tract urothelial carcinoma. ECOG5 and tumour 
stage predicted all-cause mortality. 1Hazard ratios. 2Confidence intervals. 3Organ confined 
disease. 4Non-organ confined disease. 5Eastern Cooperative Oncology group. 
Variable    
 HR1 CI2 p 
Age  1.00 0.96-1.05 0.9 
Tumour grade high vs low 1.55 0.66-3.61 0.3 
Tumour stage  NOCD4 vs OCD3  3.28 1.66-6.48 0.001 
ECOG5 1 or more vs 0 4.68 2.30-9.13 <0.001 
Supplementary table 2. Multivariate regression analyses evaluating potential predictors of 
cancer specific mortality after radical nephroureterectomy for upper tract urothelial 
carcinoma. Only tumour stage predicted cancer specific mortality in the present cohort. 
1Hazard ratios. 2Confidence intervals.  
Variable    
 HR1 CI2 p 
Tumour grade high vs low 5.64 0.67-47.4 0.11 
Tumour stage OCD vs NOCD  0.15 0.06-0.40 <0.001 
ECOG 1 or more vs 0  2.27 0.97-5.31 0.06 
Paper II - Suppl. figure 1
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